document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis year execute strategy transform generation biopharmaceutical company transformation encompass area business operation strategy divest nonpharmaceutical business implement acquisition licensing strategy know stringofpearl execute productivity transformation initiative pti divestiture include medical imaging january convatec august mead johnson december acquisition licensing transaction include kosan biosciences inc june medarex inc medarex september zymogenetics inc zymogenetics october amira pharmaceuticals inc amira september inhibitex inc inhibitex february amylin pharmaceuticals inc amylin august license collaboration arrangement continue review cost structure intent maintain modernized efficient robust balance build competitive advantage secure innovative product plan future operate segmentbiopharmaceutical additional information business segment item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country percentage total net sale significant region follow year end december dollar millions united states europe japan china canada net sale product pharmaceutical product include chemicallysynthesize drug small molecule increase portion product produce biological process typically involve recombinant dna technology call biologics small molecule drug typically administer orally form pill tablet drug delivery mechanism biologic typically administer patient injection infusion revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolic pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition business generic competition follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur japan canada sell pharmaceutical product country datum provide countrybycountry basis individual country sale significant outside japan china canada instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present net sale key product estimate basic exclusivity loss japanese chinese canadian market net sale product past currently estimate year basic exclusivity loss dollar million japan china canada key product plavix avaproavalide eliquis abilify reyataz sustiva franchise baraclude erbitux sprycel yervoy orencia nulojix onglyzakombiglyze byetta bydureon forxiga note currently estimate early year basic exclusivity loss include statutory extension exclusivity grant instance able obtain additional month exclusivity product base pediatric extension certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity indicate brand name product trademark own wholly own bms specific trademark ownership information include currently market product country region indicate uncertainty china exclusivity law result generic competition china market reference include member states european union year end december basic patent application file current member state list product instance date basic exclusivity loss different member states country basic patent obtain datum protection available data exclusivity expire july major market europe product national patent expiring specifically claim bisulfate form clopidogrel generic alternate salt form clopidogrel bisulfate market compete plavix rights commercialize abilify aripiprazole terminate right commercialize abilify terminate exclusivity period base regulatory datum protection data exclusivity expire exclusivity period relate sustiva brand include exclusivity relate combination therapy composition matter patent efavirenz expire method use patent treatment hiv infection expire pediatric exclusivity grant provide additional month period exclusivity add term patent list orange book exclusivity period relate sustiva brand include exclusivity relate combination therapy market exclusivity sustiva expect expire country data exclusivity sustiva expire february district court district delaware invalidate composition matter patent covering baraclude schedule expire face generic competition product begin biologic product approve biologics license application bla datum exclusivity expire patent specifically claim composition matter cetuximab active ingredient erbitux right commercialize cetuximab terminate exclusivity period base regulatory datum protection data exclusivity canada expire exclusivity period base method use patent composition matter patent expire exclusivity period base formulation patent summary indication intellectual property position product partner thirdparty manufacturing arrangement product applicable japan canada plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codevelope jointly market sanofi october bms sanofi announce restructuring alliance follow loss exclusivity plavix avaproavalide major market information alliance sanofi restructuring strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent expire regulatory datum exclusivity protection expire july major market europe plavix benefit national patent expire specifically claim bisulfate form clopidogrel generic alternative salt form clopidogrel bisulfate market compete obtain bulk requirement clopidogrel bisulfate sanofi prior january company sanofi finish product respective facility effective january company long finish clopidogrel bisulfate facility avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi end october bms sanofi announce restructuring alliance follow loss exclusivity plavix avaproavalide major market information alliance sanofi restructuring strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent expire march expire country data exclusivity expire august avapro october avalide composition matter patent expire canada march irbesartan manufacture company sanofi manufacture bulk requirement irbesartan finish avaproavalide facility avalide purchase bulk requirement hydrochlorothiazide thirdparty alliance restructuring bmss manufacturing obligation phase sanofi assume company manufacture supply obligation irbesartan product end eliquis eliquis apixaban oral factor inhibitor target stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorder currently approve canada japan prevention stroke systemic embolism adult patient nonvalvular atrial fibrillation nvaf risk factor use vte prevention adult patient undergo elective hip knee surgery december food drug administration fda approve eliquis reduce risk stroke systemic embolism patient nvaf apixaban discover internally alliance pfizer inc pfizer information alliance pfizer item financial statementsnote alliance collaboration composition matter patent cover apixaban expire february exclude potential patent term extension expire apply supplementary protection certificate supplementary protection certificate grant expire datum exclusivity expire composition matter patent expire canada apixaban manufacture company thirdparty product finish facility abilify abilify aripiprazole atypical antipsychotic agent adult patient schizophrenia bipolar mania disorder major depressive disorder abilify pediatric use schizophrenia bipolar disorder global commercialization agreement otsuka pharmaceutical ltd otsuka japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent cover aripiprazole term current abilify agreement expire april include grant patent term extension month pediatric extension composition matter patent force germany united kingdom france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplementary protection certificate country romania denmark datum exclusivity right commercialize expire data exclusivity canada expire obtain bulk requirement aripiprazole otsuka company otsuka finish product respective facility reyataz reyataz atazanavir sulfate protease inhibitor treatment human immunodeficiency virus hiv develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net sale entitle promote reyataz use combination norvir ritonavir non exclusive license agreement abbott laboratories amend royalty pay base percentage net sale licensing agreement gilead sciences inc gilead develop commercialize fixeddose combination contain reyataz gilead compound development market exclusivity reyataz expect expire canada china major member country japan data exclusivity expire manufacture bulk requirement atazanavir finish product facility sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen combine sustiva gilead truvada emtricitabine tenofovir disoproxil fumarate atripla complete highly active antiretroviral therapy treatment product hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider information arrangement gilead strategic alliance collaboration item financial statementsnote alliance collaboration right market efavirenz canada france germany ireland italy spain license merck inc royalty base percentage net sale composition matter patent efavirenz expire method use patent treatment hiv infection expire additional month period pediatric exclusivity add term patent market exclusivity sustiva expect expire country canada data exclusivity sustiva expire company market efavirenz japan certain atripla patent subject patent litigation time patent cover efavirenz composition matter method use challenge patent efavirenz subject litigation netherlands germany information litigation matter item financial statementsnote legal proceeding contingency obtain bulk requirement efavirenz party produce finished good facility supply party bulk efavirenz gilead responsible produce finished atripla product baraclude baraclude entecavir potent selective inhibitor hepatitis virus approve fda treatment chronic hepatitis infection baraclude discover develop internally approve market country outside include china japan february district court district delaware invalidate composition matter patent covering baraclude schedule expire face generic competition product begin information patent litigation matter item financial statementsnote legal proceeding contingency composition matter patent expire japan composition matter patent expire canada uncertainty chinas exclusivity law result generic competition china market entecavir manufacture company thirdparty product finish facility erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve treatment combination irinotecan treatment patient egfr express metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use treatment squamous cell carcinoma head neck specifically erbitux approve use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail fda approve erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbase chemotherapy fluorouracil erbitux market north america agreement imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement sign october imclone merck kgaa merck serono japan erbitux receive marketing approval japan july use treat patient advance recurrent colorectal cancer description alliance imclone strategic alliance collaboration item financial statementsnote alliance collaboration datum exclusivity expire patent specifically claim composition matter cetuximab active molecule erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire include grant patent term extension inventorship use patent challenge researcher yeda research development company ltd yeda pursuant settlement agreement execute announce december imclone sanofi yeda end worldwide litigation relate use patent sanofi yeda grant imclone worldwide license use patent datum exclusivity japan canada expire yeda right license use patent yeda license patent party result product competition erbitux occur unable assess extent competitive impact occur quantify impact yeda grant amgen inc amgen license use patent amgen receive fda approval market egfrproduct compete erbitux obtain finish good requirement cetuximab use north america lilly lilly manufacture bulk requirement cetuximab facility fill finish perform thirdparty bms oversight responsibility description supply agreement lilly manufacture quality assurance sprycel sprycel dasatinib multitargete tyrosine kinase inhibitor approve treatment adult phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate treatment adult philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy fda approve sprycel treatment adult patient newly diagnose philadelphia chromosomepositive chronic myeloid leukemia cml chronic phase sprycel internally discover strategic alliance otsuka information alliance otsuka strategic alliance collaboration item financial statementsnote alliance collaboration patent term extension grant extend term basic composition matter patent cover dasatinib june dasatinib subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency orphan drug exclusivity expire protect product generic application currently approve orphan indication majority country composition matter patent cover dasatanib expire april exclude potential term extension composition matter patent expire japan canada china manufacture bulk requirement dasatinib finish product facility yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable inoperable metastatic melanoma ipilimumab approve march july currently study indication include lung cancer adjuvant melanoma hormonerefractory prostate cancer information research development yervoy research development yervoy discover medarex codevelope company medarex subsidiary patent cover ipilimumab composition matter currently expire exclude potential patent term extension canada data exclusivity expire obtain bulk ipilimumab thirdparty manufacturer finish product party facility orencia orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment abatacept available intravenous formulation begin subcutaneous formulation orencia discover develop internally series patent cover abatacept method use patent term extension grant composition matter patent extend term patent majority country patent covering abatacept expire apply supplementary protection certificate pediatric extension supplementary protection certificate protection protection certificate grant datum exclusivity expire canada japan obtain bulk abatacept thirdparty manufacturer manufacture bulk facility finish product facility formulation nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity prevention kidney transplant rejection approve launch june approve june launch july belatacept internally discover develop patent cover belatacept composition matter expire april datum exclusivity expire june june manufacture bulk requirement belatacept finish product facility onglyza kombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicate treatment type diabete adjunct diet exercise kombiglyze saxagliptin metformin hydrochloride extendedrelease approve combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus treatment saxagliptin metformin appropriate komboglyze saxagliptin metformin immediaterelease approve combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus inadequately control maximally tolerate dose metformin treat combination saxagliptin metformin separate tablet document specifically note refer kombiglyze komboglyze kombiglyze onglyza internally discover company kombiglyze codevelope company astrazeneca plc astrazeneca worldwide japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement astrazeneca otsuka japan strategic alliance collaboration item financial statementsnote alliance collaboration patent cover saxagliptin composition matter expire march canada market exclusivity china expire manufacture bulk requirement saxagliptin facility obtain bulk metformin kombiglyze party company astrazeneca finish onglyza facility company finish kombiglyze facility byetta byettaexenatide twice daily glucagonlike peptide glp receptor agonist treatment type diabetes byetta acquire amylin acquisition august byetta internally discover amylin whollyowne subsidiary company worldwide development commercialization agreement astrazeneca byetta agreement lilly termination collaboration global development commercialization byetta bydureon company lilly process transfer right company astrazeneca information arrangement astrazeneca strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent covering exenatide expire method use patent expire datum exclusivity expire europe japan canada obtain bulk requirement exenatide party manufacture finishing take place party facility bydureon bydureon exenatide extendedrelease injectable suspension onceweekly glp receptor agonist treatment type diabetes bydureon acquire amylin acquisition august bydureon internally discover amylin whollyowne subsidiary company worldwide development commercialization agreement astrazeneca bydureon information arrangement astrazeneca strategic alliance collaboration item financial statementsnote alliance collaboration formulation patent expire data exclusivity expire europe japan bulk requirement exenatide obtain party microsphere manufacturing process require extend release formulation perform company finish product facility forxiga forxiga dapagliflozin oral sodiumglucose cotransporter sglt treatment diabete approve november adjunct diet exercise combination glucoselowere medicinal product include insulin monotherapy metforminintolerant patient currently registrational review process discussion item management discussion analysis financial condition result operation product pipeline development forxiga internally discover worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin patent cover dapagliflozin composition matter expire october manufacture bulk requirement dapagliflozin finish product facility research development invest heavily research development believe critical longterm competitiveness major facility princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development carry facility world include belgium india site supplement internal drug discovery development program alliance collaborative agreement agreement bring new product pipeline help remain cut edge technology search novel medicine drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product management continue emphasize leadership innovation productivity quality strategy success research development activity concentrate biopharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder alzheimersdementia cardiovascular diabetes hepatitis hivacquired immunodeficiency syndrome aid oncology immunologic disorder fibrotic disease continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase phase iii clinical trial design specifically support new drug application particular indication assume trial successful phase clinical trial involve small number healthy patient patient suffer indicate disease test safety proper dosing phase clinical trial involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical trial conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate process typically take thirteen year long nearly year spend phase iii latestage development consider program phase iii latestage development significant program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval failure rate compound enter phase development approximately compound enter phase iii development approximately total research development expense include cost discovery research preclinical development early lateclinical development drug formulation postcommercialization medical support market product proportionate allocation enterprisewide cost appropriate cost research development spend billion billion billion include payment thirdparty collaboration contract end employ approximately people activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense individual investigational compound market product represent expense year list latestage investigational compound phase iii clinical trial potential indication investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound patent coverage highlight include patent term extension grant asunaprevir asunaprevir oral small molecule protease inhibitor phase iii development commence treatment hepatitis virus infection patent cover asunaprevir composition matter expire daclatasvir daclatasvir oral small molecule nsa replication complex inhibitor phase iii development commence treatment hepatitis virus infection patent cover daclatasvir composition matter expire peginterferon lambda peginterferon lambda novel type interferon phase iii development commence hepatitis virus infection patent cover peginterferon lambda composition matter expire elotuzumab elotuzumab humanized monoclonal antibody investigate anticancer treatment discover pdl biopharma facet biotech corporation facet spinoff facet subsequently acquire abbott laboratory abbott abbvie inc abbvie follow spinoff abbott elotuzumab alliance abbvie phase iii trial commence multiple myeloma abbvie own patent cover elotuzumab composition matter expire nivolumab nivolumab fully human monoclonal antibody bind program death receptor nkt cell investigate anticancer treatment phase iii trial commence non small cell lung cancer renal cell cancer melanoma patent cover nivolumab composition matter expire metreleptin metreleptin acquire amylin acquisition codevelope astrazeneca metreleptin protein development treatment lipodystrophy currently registrational process patent cover metreleptin composition matter expire datum exclusivity expire year regulatory approval provide notice termination global codevelopment cocommercialization arrangement necitumumab imcf fully human monoclonal antibody investigate anticancer treatment discover imclone alliance company lilly right return lilly termination effective lilly terminate early terminate development program brivanib phase iii trial anticancer treatment potential use hepatocellular carcinoma colorectal cancer follow table list potential additional indication andor formulation key marketed product phase iii development currently regulatory review key market product potential indication andor formulation eliquis additional indication vte treatment reyataz pediatric extension baraclude pediatric extension erbitux additional indication esophageal cancer yervoy additional indication adjuvant melanoma prostate cancer nonsmall cell lung cancer small cell lung cancer additional indication firstline metastatic melanoma orencia additional indication lupus nephritis additional formulation subcutaneous japan onglyza additional use cardiovascular risk reduction pediatric extension bydureon dual chamber pen weekly suspension forxiga fix dose combination metformin follow key development currently expect occur respect significant pipeline program outcome timing expect development dependent number factor include thing availability datum outcome certain clinical trial acceptance presentation certain medical meeting andor action health authority undertake obligation publicly update information result new information future event eliquis datum available phase iii study vte treatment daclatasvir data available phase iii hepatitis virus infection combination study asunaprevir data available phase iii hepatitis virus infection combination study sprycel datum available phase iii study prostate cancer year datum available line cml yervoy data available phase iii study prostate cancer orencia phase iii start psoriatic arthritis nulojix year datum available phase iii study prevention kidney transplant rejection onglyza datum available cardiovascular risk reduction study bydureon plan submission dual chamber pen europe forxiga plan resubmission treatment type diabete datum available phase iii blood pressure study year datum available phase iii study diabetic patient history cardiovascular disease metreleptin plan submission treatment lipodystrophy strategic alliance collaboration enter strategic alliance collaboration party transfer right develop manufacture market andor sell pharmaceutical product own party alliance collaboration include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense compound lead revenue generating product profitability alliance product generally low profit alliance product share alliance partner actively pursue arrangement view alliance important complement discovery development activity strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure number alliance agreement permit collaborator terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse collaboration agreement sign strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant strategic alliance arrangement material result operation cash flow case plavix abilify material financial condition liquidity customary pharmaceutical industry term strategic alliance arrangement generally coextensive exclusivity period vary countrybycountry basis significant current alliance arrangement currently market product investigational compound describe current marketed productsinlicense sanofi september bms sanofi restructure term codevelopment cocommercialization agreement discuss effective january subject certain country receipt regulatory approval sanofi assume worldwide operation alliance exception plavix puerto rico alliance plavix market continue unchanged december term original alliance arrangement bms return sanofi right receive quarterly royalty january december terminal payment sanofi million end ongoing dispute company resolve include onetime payment million bms sanofi relate avalide supply disruption accrue pursuant master restructuring agreement company mechanism depend territory return sanofi right clopidogrel irbesartan market exception clopidogrel puerto rico company continue act operating partner majority control interest currently exist local arrangement territory territory exception clopidogrel puerto rico terminate mutual agreement product continue sell local country entity territory addition sanofi assume marketing authorization product extent currently hold company affiliate result sanofi assume control activity relate distribution commercialization medical affair clopidogrel irbesartan region pursuant master restructuring agreement relate alliance agreement sanofi assume company manufacture supply obligation irbesartan product end company manufacture bulk clopidogrel long finish clopidogrel product facility company retain right intellectual property develop alliance necessary fulfill continue obligation alliance arrangement master restructuring agreement relate alliance agreement alliance remain effect december sanofis payment terminal fee exception puerto rico alliance remain effect december agreement sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside tradename karveakarvezide plavix copromote certain country outside tradename plavix comarkete certain country outside tradename iscover prior worldwide alliance operate framework geographic territory cover certain european asian country refer territory cover puerto rico canada australia certain latin american country refer territory territory manage separate set agreement plavix puerto rico products australia mexico brazil colombia argentina separate set agreement avaproavalide puerto rico territory territory partnership exist supply finish product country territory manage contract certain central expense market research development royalty country territory structured local affiliate sanofis local affiliate comarket separate brand affiliate operate independently compete sell product different trademark copromote single brand product trademark territory comarketing country include germany spain italy irbesartan greece china clopidogrel bisulfate sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country china retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden taiwan south korea hong kong aprovelcoaprovel certain french export country prior company sanofi copromote plavix singapore sanofi act operating partner territory own financial control interest territory ownership interest territory account investment partnership entity territory equity method recognize share result equity net income affiliate share net income partnership entity tax million million million territory company sanofi copromote plavix avaproavalide canada puerto rico territory countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing country act operating partner territory own majority control interest territory consolidate partnership result territory recognize sanofis share result net earning attributable noncontrolle interest net taxis million million million recognize net sale territory territory comarkete country billion billion billion territory partnership govern series committee enumerate function power responsibilitie territory senior committee final decisionmake authority respect territory enumerate function power responsibility jurisdiction alliance arrangement terminate sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory increase combine cost good royalty exceed specify percentage net selling price product good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event lose right product applicable relevant country territory case bankruptcy insolvency material breach default party discussion strategic alliance sanofi item financial statementsnote alliance collaboration otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement exclude certain asia pacific country april company otsuka agree extend portion commercialization manufacturing agreement expect loss product exclusivity april contractual share abilify net sale recognize company pursuant extension germany france spain company receive thirdparty net sale country thirdparty customer invoice company behalf otsuka alliance revenue recognize abilify ship risk reward ownership transfer party customer exclusive right sell abilify country europe americas number countries asia country recognize net sale term abilify agreement amend purchase product otsuka perform finish manufacturing sale otsuka party customer terms extension agreement pay otsuka million amortize reduction net sale extension period unamortized balance include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify bms receive additional reimbursement otsuka sale force cost incur bms excess requirement specify agreement reimbursement net principally marketing sell administrative advertising product promotion expense abilify agreement expire april june countries country exclusive right sell abilify agreement expire later april loss exclusivity country begin january bms receive follow percentage annual net sale net sale initially recognize adjusted reflect actual level net sale share net sale billion billion billion billion billion billion billion billion billion excess billion commercialization agreement amend october require otsuka assume responsibility provide funding sale force effort effective january consideration bm pay otsuka million january responsible funding certain operating expense million million million otsuka reimburse bms sale force effort provide march begin april otsuka assume responsibility provide funding sale force effort portion abilify agreement oncology agreement describe include changeofcontrol provision acquire acquire company compete product abilify new company assume abilify agreement amend oncology agreement currently exist acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right abilify agreement amend price accord predetermine schedule agreement provide event generic competitor abilify option terminate abilify april amendment agreement previously amend remain force exercise option receive payment otsuka accord predetermine schedule oncology agreement terminate time oncology agreement continue truncated period accord predetermine schedule early termination abilify agreement immediate notice case voluntary bankruptcy minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event challenge otsuka patent right marketbymarket basis event market product direct competition abilify termination expiration abilify agreement retain right abilify recognize net sale abilify billion billion billion addition million extension payment total upfront milestone licensing payment otsuka abilify agreement million discussion oncology agreement otsuka current market productsinternally discover discussion strategic alliance otsuka item financial statementsnote alliance collaboration lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux necitumumab imcf canada japan information agreement respect necitumumab investigational compound developmentinlicense egfr agreement respect erbitux sale north america lilly receive distribution fee base flat rate net sale north america plus reimbursement certain royalty pay lilly company lilly share half profit loss evenly japan merck kgaa receive half profit loss japan party share royalty payable party pursuant formula set forth commercialization agreement purchase north american commercial requirement bulk erbitux lilly agreement expire erbitux north america september early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance retain right erbitux share codevelopment copromotion right erbitux merck kgaa japan agreement sign october expire lilly merck kgaa merck japan lilly ability terminate agreement determine commercially unreasonable continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer recognize net sale erbitux million million million discussion strategic alliance lilly item financial statementsnote alliance collaboration gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility commercialize atripla canada certain european country provide fund fieldbased sale representative support promotional effort atripla gilead recognize atripla revenue canada countries europe revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand recognize efavirenz revenue billion billion billion related atripla net sale joint venture company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version party component product appear market party right terminate joint venture acquire right combination product canada year terminate party continue receive percentage net sale base contribution bulk component atripla retain right product enter licensing agreement gilead develop commercialize fixeddose combination contain reyataz gileads cobicistat pharmacoenhance boost agent currently phase iii clinical trial increase blood level certain hiv medicine potentially allow pill daily dose cobicstat currently registrational process fda discussion strategic alliance gilead item financial statementsnote alliance collaboration current market productsinternally discover astrazeneca january enter worldwide japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement dapagliflozin sglt agreement kombiglyze codevelope astrazeneca saxagliptin agreement exclusive right develop sell onglyza japan license otsuka december june assign otsuka kyowa hakko kirin khk describe investigational compound developmentinternally discover manufacture onglyza kombiglyze certain limited exception recognize net sale key market receive million upfront milestone licensing payment astrazeneca meet certain development regulatory milestone onglyza kombiglyze receive additional million salesbased milestone meet majority cost initial development plan pay astrazeneca additional development cost generally share equally expense onglyza kombiglyze development cost net astrazenecas share research development company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis exclude japan sglt agreement receive million upfront milestone licensing payment astrazeneca include million receive january receive million development regulatory milestone dapagliflozin meet additional million salesbased milestone dapagliflozin meet majority cost initial plan pay astrazeneca additional development cost generally share equally japan astrazeneca bear substantially development cost prior approval indication expense dapagliflozin development cost net alliance partner share research development sglt agreement like saxagliptin agreement company jointly develop clinical marketing strategy share commercialization expense profit loss dapagliflozin equally global basis manufacture dapagliflozin certain limited exception recognize net sale key market respect japan astrazeneca operational cost responsibility development regulatory activity behalf collaboration relate certain trial development cost share company company jointly market product japan share commercialization expense activity split profit loss equally like rest world manufacture dapagliflozin recognize net sale japan like rest world dapagliflozin currently study phase clinical trial japan august bms astrazeneca pharmaceutical whollyowne subsidiary astrazeneca enter collaboration worldwide development commercialization amylin portfolio product include bydureon byetta symlin arrangement base framework exist diabetes alliance agreement onglyza forxiga discuss include equal sharing profit loss arise collaboration astrazeneca indicate intent establish equal governance right certain key strategic financial decision collaboration pende require antitrust approval certain international market bms receive preliminary proceed billion astrazeneca consideration enter collaboration account deferred income amortize reduction cost product sell prorata basis estimate useful life relate longlived asset assign purchase price allocation primarily intangible asset weightedaverage estimate useful life year property plant equipment weightedaverage estimate useful life year net proceed bms receive astrazeneca consideration enter collaboration subject certain adjustment include right receive additional million astrazeneca exercise option equal governance right bms astrazeneca agree share certain tax attribute relate amylin collaboration preliminary proceed billion bm receive astrazeneca include million relate sharing certain tax attribute discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration investigational compound development internally discover otsuka simultaneously extension abilify agreement april company otsuka enter oncology agreement sprycel ixempra ixabepilone include japan market oncology territory begin collaboration fee pay otsuka annually follow percentage aggregate net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product oncology territory commercial operational expense relate product oncology territory excess million begin otsuka copromote sprycel japan exercise right copromote market begin january oncology agreement expire respect sprycel ixempra include changeofcontrol provision acquire abilify agreement describe discussion abilify agreement otsuka current market productsinlicense discussion strategic alliance otsuka item financial statementsnote alliance collaboration pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover prevention treatment atrial fibrillation venous thromboembolic vte disorder pfizer fund development cost january fund receive million upfront milestone licensing payment pfizer date include million receive february receive additional million pfizer development regulatory milestone meet company jointly develop clinical marketing strategy eliquis share commercialization expense profit loss equally global basis discussion strategic alliance pfizer item financial statementsnote alliance collaboration investigational compound developmentinlicense lilly january company lilly restructure egfr commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer november bms provide notice termination collaboration agreement lilly necitumumab termination effective lilly terminate early abbvie august grant exclusive right facet biotech corporation abbvie codevelopment cocommercialization elotuzumab humanized monoclonal antibody investigate treatment multiple myeloma term agreement fund development cost elotuzumab commercialization abbott share profit loss pay tiere royalty outside solely responsible commercialization elotuzumab addition abbott receive milestone payment base certain regulatory event sale threshold achieve investigational compound developmentinternally discover otsuka january grant otsuka exclusive right japan develop commercialize onglyza agreement entitle receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan june otsuka assign right onglyza exception specific transition service khk consent assignment bms waif right copromote onglyza japan bms supply finish saxagliptin khk astrazeneca collaboration astrazeneca bms astrazeneca codevelope metreleptin treatment lipodystrophy currently registrational process japan metreleptin acquire bms amylin acquisition astrazeneca description current market product internally discoveredand item financial statementsnote alliance collaboration information collaboration collaboration february bms reckitt benckiser group plc rbl agree enter license year collaboration overthecounterproduct sell primarily mexico brazil transaction expect close second quarter subject customary closing condition regulatory approval connection collaboration rbl responsible sale distribution marketing certain regulatory matter bms responsible exclusive supply product expiration collaboration rbl right purchase remain asset business hold bms price determine base multiple sale plus cost remain inventory hold bms time rbl assume responsibility product rbl extend term supply agreement bms certain circumstance option exercise asset previously transfer rbl collaboration period revert bms bms expect receive proceed million start collaboration period allocate license right transfer rbl write option february bms medicine company enter global license year collaboration recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetic medicine company responsible sale distribution marketing regulatory matter relate recothrom bms responsible exclusive supply product bms receive upfront payment million collaboration expire february time medicine company right purchase remain asset business hold bms price determine base multiple sale plus carry cost inventory option exercise asset previously transfer medicine company collaboration period revert bms addition strategic alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz base current expectation respect expiration market exclusivity significant market license arrangement novartis reyataz expect expire japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur japan canada product certain compound outlicense party development commercialization include obtain result acquisition zymogenetic october medarex august entitle receive milestone payment compound regulatory process royalty base product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example japan canada certain market regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term japan china canada provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection region china questionable datum protection law enforceable certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file new drug application nda medicine biological product biologic license application bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file abbreviate nda anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation european commission approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity china china medicines new chemical entity generally afford year datum exclusivity approve indication dosage uncertainty china exclusivity law result generic competition china market generic copy receive regulatory approval datum exclusivity patent expiration currently unlike china patent term restoration compensate patent term lose regulatory process general chinese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity canada canada medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration currently unlike canada patent term restoration compensate patent term lose regulatory review process canada biologics generally treat chemicallysynthesized product respect patent right regulatory exclusivity health canada issue draft guidance outline additional information provide subsequent entry biologic know biosimilar product generic biologic order review application marketing approval rest world country outside japan china canada wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar switzerland develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical government regulation price constraint field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information product provide information response unsolicite inquiry doctor medical professional manage care organization operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new product new use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage global gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler maintain inventory level month demand ima large wholesaler expire march ima expire december subject certain termination provision reach agreement principal large wholesaler subject negotiation execution final agreement extend termination date ima december subject certain termination provision number define market outside establish scale distributor model medically necessary drug available patient continue marketing authorization trademark product contract service fullservice distributor provide distribution logistic regulatory pharmacovigilance sale advertising promotion certain product contract clearly define term condition service provide supply firm order period monitor inmarket sale forecast ensure reasonable inventory level product sale maintain fully continuously meet demand product distributor territory responsibility sale distributorbase market represent company net sale competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service research development new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion sale product short period time rate sale decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval ema obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential different national pricing reimbursement law lead significant parallel trade flow healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase march government enact healthcare reform legislation sign law patient protection affordable care act reconciliation bill contain package change healthcare bill legislation make extensive change current system healthcare insurance benefit intend broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business new healthcare law implement example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion drug pricing program public health service act require provide percent discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare discussion rebate program item management discussion analysis financial condition result operationsnet sale critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing government regulation price constraint pharmaceutical manufacturing facility locate puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts rely party manufacture supply certain active ingredient necessary manufacture product include plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia yervoy onglyza kombiglyze forxiga maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturer manufacture orencia thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet complex processing requirement biologic business performance prospect negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million million capital project undertake specifically meet environmental requirement believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee december employ approximately people foreign operation significant operation outside conduct subsidiary distributor geographic breakdown net sale table caption geographic area item financial statementsnote business segment information discussion net sale geographic area item management discussion analysis financial condition result operationsnet sale international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net unfavorable impact growth rate revenue predict certainty future change foreign exchange rate effect growth rate revenue attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation face intense competition biopharmaceutical manufacturer include innovative medicine lowerprice generic product competition include lowerpriced generic version product major challenge internationally face patent expiration increasingly aggressive generic competition competition include new product develop competitor low price real perceive superior efficacy benefit safety risk profile competitive product technological advance patent attain competitor iii earlierthanexpecte competition generic company clinical study result product competitor product business combination competitor major customer compete interest external partnership develop bring new product market experience limited market access real perceive difference value proposition product compare competitor possible lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value usually realize period market exclusivity country market exclusivity expire generic version product approve market usually substantial rapid decline product sale market exclusivity product base patent right andor certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file market addition patent environment outside unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version product approve market addition prior expiration datum exclusivity competitor seek regulatory approval submit clinical trial datum obtain marketing approval manufacturer generic product increasingly seek challenge patent expire key patent cover key product atripla baraclude sprycel currently subject patent litigation case generic manufacturer choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation example face generic competition baraclude begin follow federal court decision invalidate composition matter patent february assurance particular product enjoy market exclusivity period time appear estimate disclose increased pricing pressure restriction abroad manage care organization institutional purchaser government agency program negatively affect net sale profit margin pharmaceutical product continue subject increase price pressure restriction region world include limit rule practice manage care organization institutional governmental purchasers judicial decision governmental law regulation medicare medicaid healthcare reform include patient protection affordable care act potential additional healthcare reform measure iii potential impact importation restriction legislative andor regulatory change pharmaceutical reimbursement medicare formularie product pricing general delay gain reimbursement andor reduction reimbursement amount country governmentmandate costcontainment program government price erosion mechanism europe result deflation pharmaceutical product pricing development technology andor industry practice directly indirectly impact reimbursement policy practice thirdparty payer vii limited market access real perceive difference value proposition product compare compete product experience difficulty delay development commercialization new product develop commercialize new product include inherent risk uncertainty compound product appear promise development fail reach market expect optimal timeframe fail reach market approve product extension additional indication include efficacy safety concern delay denial necessary regulatory approval delay difficulty produce product commercial scale level excessive cost manufacture product failure enter successfully implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product failure product achieve maintain commercial viability change regulatory approval process cause delay denial new product approval observe recent trend food drug administration delay approval decision new product announce action date month long regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product potentially negative impact net sale earning product acquire result significant impairment process research development intangible asset certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program noncash impairment charge material billion impairment bms record finally natural manmade disaster sabotage research development labs compound library andor loss key molecule intermediary negatively impact product development cycle failure execute business strategy adversely impact growth profitability biopharmaceutical company focus innovative product high unmet medical need build foundation future strategy grow key marketed product advance latestage pipeline manage cost able consistently replenish innovative pipeline internal research development transaction party competition major pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction able realize expect increase efficiency effectiveness continuous improvement initiative change structure operation include recent reorganization commercial operation creation enterprise service organization addition realize synergy expect benefit acquisition divestiture merger alliance restructuring strategic initiative long expect complete encounter difficulty include need regulatory approval applicable unable support grow currently market product successfully execute launch newly approve product advance latestage pipeline manage cost effectively experience significant material negative impact operating result financial condition addition failure hire retain personnel right expertise experience critical operation adversely impact execution business strategy business acquire underperform able successfully integrate exist business continue support pipeline licensing acquisition strategy august acquire amylin pharmaceuticals inc amylin biopharmaceutical company dedicate discovery development commercialization innovative medicine patient diabete metabolic disease amylin acquire business product technology underperform relative expectation negatively impact financial result include potential impairment charge acquire intangible asset include identifiable intangible asset attribute amylin acquisition billion acquisition date future sale profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include research development manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii company culture compensation structure human resource activity tax consideration depend certain key product net sale cash flow earning historically derive majority revenue earning key product example plavix represent revenue dependent single product derive significant revenue key product abilify net sale billion represent revenue reyataz sustiva franchise combine net sale billion represent approximately revenue baraclude sprycel orencia net sale exceed billion reduction net sale product significantly negatively impact net sale cash flow earning change foreign law regulation negatively affect net sale profit margin subject new government law regulation additional healthcare reform initiative country include additional mandatory discount change corporate tax regulation include propose budget deficit reduction package include limit foreign tax credit tax certain tax haven tax certain excess income transfer intellectual property limiting disallow certain deduction operate interest expense change rule earning repatriation eliminate certain tax credit change tax rate phase currently available tax benefit certain foreign country change tax law iii new law regulation judicial governmental decision affect pricing drug reimbursement receivable repayment access marketing jurisdiction change intellectual property law change accounting standard increase datum privacy regulation enforcement vii emerge new requirement payment healthcare professional viii matter compulsory license alter protection afford product legal regulatory change negatively affect business operating result financial condition company emerge legislation reduce budget deficit country enact likely reduce operating result product label change market product potentially result unexpected safety efficacy concern negative impact product sale regulatory authority change label pharmaceutical product time include product market year change result additional datum postmarkete study headtohead trial report adverse event study identify biomarker objective characteristic indicate particular response product therapy study produce important additional information product new information add product label affect safety andor efficacy profile product lead product recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine labeling change base study limit patient population change label plavix erbitux year ago study provide additional information sponsor sponsor competitor insurance company government institution manage care organization influential scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negative impact sale product extent patient population product labeling limited additionally certain study result especially headtohead trial affect product formulary listing adversely affect sale experience difficulty delay manufacture distribution sale product product supply relate patient access product negatively impact thing seizure recall product force closing manufacture plant supply chain continuity include natural manmade disaster facility critical supplier vendor failure failure vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure sole source single source supplier provide necessary raw material supply finish good extend period time failure thirdparty manufacturer supply finish product time construction regulatory approval delay relate new facility expansion exist facility include intended support future demand biologic product vii failure meet new emerge regulation require product track distribution channel unique identifier viii manufacturing distribution issue include limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation business interruption adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product potentially adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute sale marketing practice internationally iii adverse decision litigation include product liability commercial case recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection antibribery foreign corrupt practice act antibribery act law viii environmental health safety matter tax liability depend party meet contractual regulatory obligation rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain human resource finance information technology functional service meet contractual regulatory obligation relation arrangement thirdparty provider locate market subject political risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact company operation result addition party violate allege violate law regulation include foreign corrupt practice act bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence increasingly dependent information technology system infrastructure face certain risk include cyber security datum leakage significant breakdown invasion corruption destruction interruption critical information technology system infrastructure employee authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity data leakage confidential information experience business interruption information theft reputational damage malware cyber attack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue invest industry appropriate protection monitor practice datum information technology reduce risk continue monitor system ongoing basis current potential threat assurance effort prevent breakdown breach party provider database system adversely affect business expansion social medium platform present new risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment social network web site damage reputation brand image goodwill disclosure nonpublic company sensitive information external medium channel lead information loss structured process place secure protect information identify new point entry social medium continue expand present new challenge adverse change global regional local economic condition adversely affect profitability world major economy hold historicallyhigh debt level experience slow economic growth high unemployment european sovereign debt crisis strained government spending create capital market volatility significant operation europe include manufacturing exposure customer credit risk europe include governmentguaranteed hospital receivables likely increase ability factor receivables limited addition future pension plan funding requirement continue sensitive global economic condition relate impact equity market expose commercial risk economic factor control pose significant challenge underlie profitability change foreign currency exchange rate interest rate material adverse effect operating result liquidity significant operation outside net sale operation outside account approximately net sale expose fluctuation foreign currency exchange rate difficult mitigate expose change interest rate ability access money market andor capital market impede adverse liquidity market condition occur illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand addition theft inventory warehouse plant intransit properly store sell unauthorized channel adversely impact patient safety reputation business item unresolved staff comment item property world headquarter locate park avenue new york lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe rest world total portion manufacturing location property own lease research development administration storage distribution information property item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item safety disclosure applicable executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti executive vice president president worldwide pharmaceutical chief executive officer director division company member senior management team executive vice president chief operating officer worldwide pharmaceutical division company executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charle bancroft vice president finance worldwide pharmaceutical division executive vice president chief financial officer company member senior management team chief financial officer company present executive vice president chief financial officer company giovanni caforio senior vice president oncology worldwide pharmaceutical president pharmaceuticals division company member senior management team senior vice president oncology global commercialization senior vice president oncology immunoscience global commercialization present president pharmaceuticals joseph caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller beatrice cazala president emea worldwide medicine international executive vice president commercial operation president emea asia pacific worldwide medicine international member senior management team president global commercialization president europe senior vice president commercial operation president global commercialization europe emerge market present executive vice president commercial operation francis cuss bchir frcp senior vice president discovery exploratory clinical research senior vice president research present senior vice president research research development member senior management team brian daniels senior vice president global clinical development research senior vice president global development development division company medical affair research development present senior vice president global development medical affair member senior management team research development john elicker senior director investor relation senior vice president public affairs investor vice president investor relation relation senior vice president investor relation member senior management team present senior vice president public affairs investor relation france heller head strategic alliance novartis pharmaceutical senior vice president business development executive vice president exelixis member senior management team instructor stanford university present senior vice president business development sandra leung vice president corporate secretary act general counsel general counsel corporate secretary present general counsel corporate secretary member senior management team samuel moe senior vice president worldwide strategy operation senior vice president strategic planning analysis senior vice president strategy member senior management team present senior vice president strategic planning analysis louis schmukler senior vice president pharmaceutical operating unit wyeth president global manufacturing supply senior vice president specialtybiotechnology operating unit pfizer member senior management team present president global manufacturing supply elliott sigal phd executive vice president chief scientific officer president research executive vice president chief scientific officer development president research development director present executive vice president chief scientific officer president member senior management team research development director company paul von autenrie vice president chief information officer senior vice president enterprise service chief senior vice president chief information officer information officer present senior vice president enterprise service chief information member senior management team officer item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present high low high low common quarter second quarter quarter fourth quarter prefer quarter second quarter quarter fourth quarter fourth quarter observable trade companys prefer stock holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow dividend share pay quarter indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february issuer purchase equity security follow table summarize surrender repurchase equity security month period end december total number share purchase publicly approximate dollar value average price announce share total number pay plan purchase period share purchaseda sharea programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december total number share purchase total number share purchase publicly announce program different share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation board director authorize repurchase billion common stock june board director increase authorization repurchase common stock additional billion repurchase program expiration date suspend discontinued time item select financial datum year financial summary amount million share datum income statement dataa net sale continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtc equity discussion item affect comparability result year item management discussion analysis financial condition result operationsnon gaap financial measure marketable security include current noncurrent asset include current portion longterm debt item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease license manufacture market distribute sell pharmaceutical product global basis follow key event transaction occurred discuss detail strategy product pipeline development result operation section management discussion analysis net sale earning decline result loss exclusivity plavix clopidogrel bisulfate avaproavalide irbesartanirbesartan hydrochlorothiazide receive significant regulatory approval pertain eliquis apixaban stroke prevention patient nonvalvular atrial fibrillation nvaf forxiga dapagliflozin orencia abatacept subcutaneous formulation acquire amylin pharmaceuticals inc amylin expand diabetes alliance arrangement astrazeneca plc astrazeneca include amylinrelate product discontinue development bm inx compound acquire acquisition inhibitex inc inhibitex treat hepatitis virus infection interest patient safety result billion pretax impairment charge highlight follow table summary financial highlight year end december dollar million share datum net sale total expense earning income taxis provision forbenefit income taxis effective taxbenefit rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure nongaap financial measure business environment pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect sale product include product efficacy safety price demand competition costeffectiveness marketing effectiveness market access product label quality control quality assurance manufacturing operation research development new product successfully compete healthcare industry demonstrate product offer medical benefit cost advantage new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future manufacture brand product price high generic product generic competition lead challenge pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize market exclusivity period long protect patent subject new compete product form generic brand exclusivity loss experience significant reduction product sale short period time competitor seek approval biological product biologic license application bla file safety efficacy datum address challenge biologic manufacture involve complex process cost pharmaceutical operation healthcare legislation enact abbreviate path regulatory approval generic version biological product path approval biosimilar product healthcare legislation significantly affect regulatory data exclusivity biological product legislation provide regulatory mechanism allow regulatory approval biologic drug similar generic copy innovative drug basis extensive datum require bla possible time reasonably assess impact biosimilar legislation company globally healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale march government enact healthcare reform legislation sign law patient protection affordable care act reconciliation bill contain package change healthcare bill continue experience additional financial cost certain change business healthcare law provision effective aggregate financial impact healthcare reform year depend number factor include limited pende implementation guidance potential change sale volume eligible new rebate discount fee impact cost sharing arrangement certain alliance partner future net sale beginning potentially positively impact expect increase number people healthcare coverage patient protection affordable care act market outside operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing example pricing freedom limited operation profit control plan germany operation reference price system european country continue fiscal challenge healthcare payer include government agency reduce expect continue reduce cost healthcare action directly indirectly impose additional price restriction company face significant delay market access new product year elapse drug approval new medicine available country growth manage care organization mcos significantly impact competition healthcare industry mco seek reduce healthcare expenditure participant volume purchase longterm contractual discount pharmaceutical provider market potential create large pool participant marketing prescription drug mco important strategy company compete inclusion mco formulary generally successful key product include believe development manage care industry include continued consolidation continue downward pressure price pharmaceutical biotechnology production process complex highly regulate vary widely product shift add manufacturing capacity usually lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic large percentage product portfolio continue maintain supply arrangement thirdparty manufacturer incur substantial investment increase internal capacity produce biologic commercial scale fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts maintain competitive position market strive uphold position depend success discover develop deliver innovative costeffective product help patient prevail disease subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter item financial statementsnote legal proceeding contingency strategy past year transform company focus biopharmaceutical company continue focus sustain business building foundation future grow new key marketed product advance pipeline portfolio managing cost expect portfolio increasingly diversified product geography year experience substantial exclusivity loss year plavix avaproavalide billion net sale prepare number year expect experience rapid precipitous material decline plavix avaproavalide net sale reduction net income operate cash flow event norm industry company experience loss exclusivity significant product face additional exclusivity loss come year face significant challenge increasingly complex global regulatory environment global economic uncertainty particularly european union believe strategy grow new market product robust research development pipeline particularly therapeutic area immunooncology cardiovascularmetabolic disease virology position future continue expand biologic capability rely significantly small molecule strongest reliable starting point discover potential new medicine large molecule biologic derive recombinant dna technology increasingly important currently pipeline compound biologic key marketed product include yervoy ipilimumab continue support pipeline licensing acquisition strategy refer string pearl quarter acquire amylin biopharmaceutical company dedicate discovery development commercialization innovative medicine patient diabete metabolic disease follow completion acquisition amylin enter collaboration astrazeneca pharmaceutical wholly own subsidiary astrazeneca build exist alliance expand collaboration strategy currently integrate amylin business development manufacture commercial operation seek build relationship academic organization innovative program capabilitie complement internal effort product pipeline development manage research development program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth consider program enter phase iii development significant program constitute latestage development pipeline phase iii development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual expense individual investigational compound market product represent expense year expect latestage development program market latestage development program program potentially impact revenue earning year follow recent significant development market product latestage pipeline eliquis oral factor inhibitor target stroke prevention nvaf prevention treatment venous thromboembolic vte disorder eliquis strategic alliance pfizer inc pfizer december food drug administration fda approve eliquis reduce risk stroke systemic embolism patient nvaf eliquis receive regulatory approval indication japan canada december november south korea january december company announce result phase iii amplifyext trial evaluate treatment eliquis compare placebo year period prevention recurrent vte patient complete month anticoagulation treatment vte include deep vein thrombosis pulmonary embolism trial extend treatment eliquis twice daily demonstrate superiority versus placebo reduction composite endpoint symptomatic recurrent vte death cause eliquis superior placebo predefine secondary efficacy outcome recurrent vte vterelate death rate primary safety outcome major bleeding comparable treatment group october company announce publication lancet reduction stroke systemic embolism major bleeding mortality demonstrate eliquis compare warfarin aristotle trial consistent wide range stroke bleed risk score patient nvaf march additional analysis aristotle averroes clinical trial present american college cardiologys annual scientific session forxiga oral sodiumglucose cotransporter sglt inhibitor treatment diabete alliance astrazeneca november approve forxiga treatment type diabete june american diabetes association scientific session company astrazeneca announce result phase iii clinical study show forxiga demonstrate significant reduction blood sugar level glycosylate hemoglobin level hbac compare placebo week agent add exist sitagliptin therapy metformin adult patient type diabetes result maintain week extension similar result observe datum stratify background therapy study demonstrate significant reduction total body weight fast plasma glucose level patient take forxiga add sitigliptin metformin result maintain duration study january fda issue complete response letter crl nda dapagliflozin crl request additional clinical datum allow well assessment benefitrisk profile dapagliflozin company continue work closely fda determine appropriate step dapagliflozin application ongoing discussion health authority countrie application procedure company meet fda path forward potential approval forxiga company provide additional datum ongoing study fda expect able resubmit nda forxiga mid time company expect fda sixmonth period review resubmission hold advisory committee meeting hepatitis portfolio peginterferon lambda novel potential firstinclass type interferon development daclatasvir nsa replication complex inhibitor development asunaprevir protease inhibitor development november company announce result global dlite phase iib study week regiman combine investigational compound peginterferon lambdaa investigational directacting antiviral daa daclatasvir ribavirin achieve sustain virologic response week posttreatment treatmentnave genotype chronic hepatitis virus infection patient achieve protocoldefine response november company announce phase datum demonstrate week triple daa treatment regime daclatasvir asunaprevir bms nsb nonnucleoside polymerase inhibitor achieve sustain virologic response week posttreatment treatment nave genotype chronic hepatitis virus infection patient november company announce phase datum demonstrate dual regiment daclatasvir asunaprevir interferon ribavarin achieve high rate sustain virologic response week posttreatment patient genotype hepatitis virus infection prior null responder alfa interferon ribavarin elotuzumab antic antibody investigation treatment multiple myeloma december company announce result small randomize phase study patient previously treat myeloma dose test mgkg mgkg combination lenalidomide lowdose dexamethasone mgkg arm median progressionfree survival pfs time disease progression death reach month follow objective response rate orr patient receive elotuzumab dose mgkg median pfs months orr necitumumab novel target cancer therapy nonsmall cell lung cancer november provide notice termination global codevelopment cocommercialization arrangement necitumumab imcf fully human monoclonal antibody investigate anticancer treatment discover imclone alliance company eli lilly company lilly right return lilly termination effective lilly terminate early sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv february company announce fda grant additional sixmonth period exclusivity market sustiva exclusivity sustiva schedule expire march baraclude entecavir oral antiviral agent treatment chronic hepatitis february district court district delaware invalidate composition matter patent covering baraclude schedule expire october labeling update baraclude approve fda include datum african americans liver transplant recipient chronic hepatitis infection erbitux cetuximab monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux alliance lilly july fda grant approval erbitux combination chemotherapy regimen folfiri irinotecan fluorouracil leucovorin firstline treatment patient kra mutationnegative epidermal growth factor receptorexpresse metastatic colorectal cancer determine fda approve test use april fda issue crl supplemental biologic license application sbla firstline nonsmall cell lung cancer state base current datum package firstline indication erbitux combination vinorelbine cisplatin approvable lilly company plan resubmit filing yervoy ipilimumab monoclonal antibody treatment patient unresectable inoperable metastatic melanoma november national institute health clinical excellence nice recommend yervoy approve treatment previously treat metastatic advanced melanoma final appraisal determination important recommendation enable eligible patient england wale routinely access treatment yervoy national health service september company announce european society medical oncology congress longterm followup data study evaluate newlydiagnose patient treat yervoy mgkg combination dacarbazine versus dacarbazine fiveyear followup data rollover study evaluate patient yervoy mgkg mgkg survival rate observe study year stable high patient treat yervoy plus dacarbazine versus patient receive dacarbazine estimate survival rate study remain unchanged relatively stable year compare year newlydiagnose patient previouslydiagnose patient orencia fusion protein indicate rheumatoid arthritis october grant marketing authorization subcutaneous formulation orencia combination methotrexate treatment moderate severe active adult june european league rheumatism annual european congress rheumatology company announce ample headto head trial patient compare subcutaneous formulation orencia humira adalimumab background methotrexate mtx biologic nave patient moderate severe meet primary endpoint measure noninferiority demonstrate orencia plus mtx achieve comparable rate efficacy american college rheumatology criterion percent acr response year humira plus mtx company announce fda approve company biologic manufacturing facility deven massachusetts commercial production orencia nulojix belatacept fusion protein novel immunosuppressive activity prevention kidney transplant rejection june american transplant congress company announce new fouryear result longterm extension lte benefit benefitext clinical trial nulojix tcell costimulation blocker indicate prophylaxis organ rejection adult epsteinbarr virus seropositive patient receive kidney transplant combination basiliximab induction mycophenolate mofetil corticosteroids result show safety profile nulojix year consistent compare result year new safety signal identify renal function benefit versus cyclosporine maintain year patient enrol lte benefit benefitext trial onglyzakombiglyze saxagliptinonce daily combination saxagliptin metformin hydrochloride extendedrelease treatment type diabete strategic alliance astrazeneca july company astrazeneca announce world congress heart disease result analysis show onglyza demonstrate improvement key measure blood sugar control glycosylate hemoglobin level hbac fast plasma glucose fpg post prandial glucose ppg compare placebo adult patient type diabete high risk cardiovascular disease addition august company discontinue development bms decision interest patient safety item financial statementsnote goodwill intangible asset information result operation net sale composition change net sale follow year end december net sale analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange united statesa europeb rest worldc otherd total include puerto rico include russia turkey include japan china canada australia brazil country include royaltyrelate revenue sale attribute supply agreement change excess change net sale attribute volume reflect recent exclusivity loss plavix avaproavalide partially offset increase demand key product addition byetta bydureon symlin follow completion acquisition amylin million change net sale attribute volume reflect launch yervoy increase demand key product partially offset decrease prescription demand avaproavalide plavix change net sale attribute price period result high average net selling price plavix abilify partially offset reduction contractual share abilify net sale reduction high rebate discount result healthcare reform legislation key product discussion sale key product net sales europe decrease primarily unfavorable foreign exchange low sale certain mature brand divestiture generic competition generic competition plavix avaproavalide partially offset sale growth key product net sales europe increase favorable foreign exchange sale growth key product offset previously mention low sale certain mature brand generic competition plavix avaproavalide net sale period negatively impact continue fiscal challenge european country healthcare payer include government agency reduce expect continue reduce cost healthcare action directly indirectly impose additional price reduction measure include limited mandatory discount rebate price reduction restrictive measure net sale rest world decrease growth certain key product japan china south korea offset generic competition plavix avaproavalide time government purchase certain country lower sale mature brand generic competition divestiture net sale rest world increase primarily growth certain key product japan china south korea favorable foreign exchange partially offset generic competition avaproavalide low sale mature brand generic competition divestiture net sale increase enhanced royaltyrelate revenue high sale attribute active pharmaceutical ingredient supply agreement result recent divestiture manufacture facility restructure alliance agreement net sale expect continue increase result high royalty alliance revenue attribute restructure sanofi agreement new matureoverthecounter brand collaborative agreement single country outside contribute total net sale general business seasonal information pharmaceutical prescriber demand reference table estimated endus demand set forth comparison change net sale estimate total prescription growth retail mail order customer certain key product nonu net sale categorize base location customer revenue reduced present net grosstonet sale adjustment describe critical accounting policy reconciliation gross sale net sale significant category grosstonet sale adjustment follow year end december change dollar million gross sale grosstonet sale adjustment chargeback related government program cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet sale adjustment net sale activity end balance significant category grosstonet sale reserve adjustment follow healthcare chargeback rebate related government cash contract medicaid sale dollar million program discount discount rebate return adjustment total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december provision relate sale current period provision relate sale prior period return payment amylin acquisition impact foreign currency translation balance december grosstonet sale adjustment rate primarily function changes sale mix contractual legislative discount rebate grosstonet sale adjustment decrease increase grosstonet adjustment category sale return adjustment decrease result low plavix sale follow loss exclusivity manage healthcare rebate contract discount decrease million reduction estimate medicare coverage gap discount attributable prior period rebate receive actual invoice nonrenewal plavix contract discount medicare program january rebate discount increase discount patient medicare coverage gap medicaid rebate decrease million reduction estimate manage medicaid rebate attributable prior period receive actual invoice medicaid rebate increase year impact expansion rebate drug risk base medicaid manage care plan high average net selling price plavix high medicaid channel sale provision sale return increase result loss exclusivity plavix avaproavalide march sale return reserve product december million determine consider factor include estimate inventory level distribution channel accordance company policy product eligible return month prior month product expiration additional adjustment reserve require future revise estimate assumption include actual return generally expect occur sale return include million reduction million return reserve establish connection recall certain lot avalide low return expect adjustment increase result copay coupon program present grosstonet adjustment table contractual share abilify atripla grosstonet sale adjustment approximately billion billion billion increase primarily attribute additional rebate discount require healthcare reform key product net sale key product represent total net sale follow table present international net sale key product percentage change prior period foreign exchange impact compare prior period commentary detail reason significant variance key product provide change attributable year end december change foreign exchange dollar million key product plavix clopidogrel bisulfate nonus avaproavalide irbesartanirbesartanhydrochlorothiazide nonus eliquis apixaban nonus abilify aripiprazole nonus reyataz atazanavir sulfate nonus sustiva efavirenz franchise nonus baraclude entecavir nonus erbitux cetuximab nonus sprycel dasatinib nonus yervoy ipilimumab nonus orencia abatacept nonus nulojix belatacept nonus onglyzakombiglyze saxagliptinsaxagliptin metformin nonus change excess change attributable year end december change foreign exchange dollar million key product continue byetta exenatide nonus bydureon exenatide extendedrelease injectable suspension nonus mature product nonus change excess plavix platelet aggregation inhibitor alliance sanofi net sale decrease continue decrease loss exclusivity net sale increase primarily high average net selling price estimate total prescription demand decrease international net sale continue negatively impact generic clopidogrel product canada australia avaproavalide know aprovelkarvea angiotensin receptor blocker treatment hypertension diabetic nephropathy sanofi alliance net sale decrease loss exclusivity march decrease market share loss subsequent avalide supply shortage quarter associate previously report recall decrease net sale partially offset high average net selling price estimate return total estimate prescription demand decrease international net sale decrease period low demand include generic competition certain markets canada eliquis oral factor inhibitor target stroke prevention atrial fibrillation prevention treatment vte disorder eliquis strategic alliance pfizer eliquis approve prevention stroke systemic embolism adult patient nvaf december eliquis approve vte prevention launch limited number country begin eliquis approve prevention stroke systemic embolism adult patient nvaf november eliquis approve december japanese ministry health labor welfare prevention ischemic stroke systemic embolism patient nvaf abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka net sale increase high average net selling price million reduction bmss share estimate customer rebate discount attributable base actual invoice receive partially offset fluctuation retail buying pattern net sale increase high overall demand high average net selling price net sale period negatively impact reduction contractual share net sale expect continue negatively impact result reduction bmss contractual share abilify net sale estimate approximately estimate total prescription demand increase international net sale increase period primarily high demand international net sale impact unfavorable foreign exchange favorable foreign exchange reyataz protease inhibitor treatment human immunodeficiency virus hiv net sale increase high average net selling price estimate total prescription demand decrease increase international net sale decrease unfavorable foreign exchange time government purchase certain country low demand result compete product international net sale increase high demand sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate product sell joint venture gilead net sale increase period primarily high demand high average net selling price estimate total prescription demand decrease increase international net sale decrease unfavorable foreign exchange international net sale increase primarily high demand baraclude oral antiviral agent treatment chronic hepatitis net sale period increase primarily high demand experience rapid significant decline net sale begin possible generic competition follow federal court decision february invalidate composition matter patent erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux strategic alliance lilly sell exclusively net sale remain relatively flat increase primarily high demand sprycel oral inhibitor multiple tyrosine kinase indicate treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel strategic alliance otsuka net sale period increase primarily high demand high average net selling price estimate total prescription demand increase international net sale period increase primarily high demand international net sale impact unfavorable foreign exchange favorable foreign exchange demand positively impact approval sprycel firstline treatment adult patient newly diagnose philadelphia chromosome positive chronic myeloid leukemia chronic phase fourth quarter yervoy monoclonal antibody treatment patient unresectable inoperable metastatic melanoma yervoy net sale increase high demand launch second quarter continue launch number international country second quarter orencia fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy net sale increase period primarily high demand include launch orencia subcutaneous formulation fourth quarter high average net selling price international net sale increase period primarily high demand include launch orencia certain european market begin second quarter international net sale impact unfavorable foreign exchange favorable foreign exchange nulojix fusion protein novel immunosuppressive activity target prevention kidney transplant rejection nulojix approve launch onglyzakombiglyze know onglyzakomboglyze oncedaily oral tablet treatment type diabete strategic alliance astrazeneca net sale onglyzakombiglyze increase period primarily high overall demand high average net selling price kombiglyze launch fourth quarter international net sale increase period primarily high demand partially offset unfavorable foreign exchange byetta twice daily glucagonlike peptide glp receptor agonist treatment type diabetes byetta net sale include result follow completion acquisition amylin quarter bydureon onceweekly glp receptor agonist treatment type diabetes bydureon launch amylin quarter second quarter net sale include result follow completion acquisition amylin quarter mature product include product include lose exclusivity major market overthecounter brand royalty relate revenue net sale continue decrease generic erosion certain product partially offset sale symlin follow completion amylin acquisition quarter international net sale decrease period continued generic erosion certain brand unfavorable foreign exchange estimate prescription change datum provide report include information retail mail order channel reflect product demand channel hospital home health care clinic federal facility include veteran administration hospital longterm care datum provide wolter kluwer health sprycel base source prescription audit sprycel demand base information nextgeneration prescription service version national prescription audit provide ims health im datum product respective service provider recordkeeping projection process subject inherent limitation estimate base sampling include margin error continuously seek improve quality estimate prescription change amount ultimate patientconsumer demand review calculation methodology employ analyze internal thirdparty datum expect continue review refine methodology process calculation estimate monitor quality party datum calculation calculate estimate total prescription change weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription mail order prescription typically reflect day prescription retail prescription typically reflect day prescription calculation derive multiply mail order prescription datum factor approximate add retail prescription believe calculation estimate total prescription change base weightedaverage approach provide superior estimate total prescription demand retail mail order channel use methodology internal demand report estimate endus demand follow table set forth key product sell year end december change report net sales year estimate total prescription change retail mail order channel calculate base thirdparty datum weightedaverage basis iii month inventory hand wholesale distribution channel year end december december change change net sale total prescription month hand dollar millions plavix avaproavalide abilify reyataz sustiva franchisea baraclude erbituxb sprycel yervoybd orenciac nulojixbd onglyzakombiglyze byettae bydureone sustiva franchise include sale sustiva revenue bulk efavirenz include combination therapy atripla month hand relate sustiva erbitux yervoy nulojix parenterally administer product prescriptionlevel datum physician write prescription product orencia intravenous formulation parenterally administer product prescriptionlevel datum physician write prescription product orencia subcutaneous formulation orencia parenterally administer launch fourth quarter orencia sale million million yervoy nulojix launch second quarter byetta bydureon net sale include result follow completion acquisition amylin quarter change excess pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand product material date indicate product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september plavix month inventory hand compare month inventory hand december loss exclusivity expect gradual decrease inventory hand plavix occur year product wholesale distribution channel continue work return level inventory hand wholesale retail distribution channel consider assess sale return reserve establish december avaproavalide month inventory hand compare inventory hand december loss exclusivity march onetime increase million inventory wholesale retail distribution channel correspond transition avaproavalide manufacturing sanofi pursuant restructure agreement level inventory hand wholesale retail distribution channel consider assess sale return reserve establish december dafalgan analgesic product sell principally europe month inventory hand direct customer compare month inventory hand december level inventory hand primarily order pattern pharmacist france fervex cold flu product month inventory hand internationally direct customer compare month inventory hand december level inventory hand decrease follow peak flu season remain inventory hand primarily attributable order pattern pharmacist france luftal antacid product month inventory hand internationally direct customer compare month inventory hand december level inventory hand primarily government purchasing pattern brazil product sell exclusively wholesaler distributor generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product provide distributor factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense change excess cost product sell cost product sell consist material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost settlement foreign currency forward contract hedge forecast intercompany inventory purchase transaction essentially cost manage global manufacturing supply organization cost product include royalty profit sharing attribute license product alliance amortization acquire develop technology cost business combination milestone payment occur regulatory approval cost product sell vary period result product mix particularly result royalty profit sharing expense connection alliance price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility give high percentage total cost denominate foreign currency cost product sell percentage net sale decrease cost product sell primarily attribute low sale volume follow loss exclusivity plavix avaproavalide result low royalty connection sanofi alliance favorable foreign exchange partially offset impairment charge discuss high amortization cost result amylin acquisition net amortization amylin collaboration proceed impairment charge million recognize million relate partial writedown fair value develop technology cost relate nonkey product recothrom acquire acquisition zymogenetics inc zymogenetics develop technology impairment charge result continued competitive pricing pressure reduction undiscounte project cash flow carry value intangible asset impairment charge calculate difference fair value asset base discount value estimate future cash flow carry value intangible asset remain million impairment charge relate abandonment manufacturing facility result outsource manufacturing process increase primarily attributable high sale volume result additional royalty collaboration fee profit sharing expense unfavorable foreign exchange marketing sell administrative marketing sell administrative expense consist salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global corporate organization finance law information technology human resource marketing selling administrative expense increase slightly primarily result amylin acquisition million include million relate accelerated vest stock option restrict stock unit partially offset reduction salesrelated activity plavix avaproavalide marketing sell administrative expense impact favorable foreign exchange increase attribute annual pharmaceutical company fee unfavorable foreign exchange high marketing cost support new launch key product less extent high bad debt expense charitable funding information technology expense annual pharmaceutical company fee million million information annual pharmaceutical company fee refer item businessgovernment regulation price constraint advertising product promotion advertising product promotion expense consist related media sample direct consumer program decrease primarily attribute low spending promotion plavix avaproavalide abilify certain mature brand coincide product life cycle research development research development expense consist salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost total research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost facility information technology employee stock compensation cost appropriate cost expense include thirdparty licensing fee typically pay upfront regulatory contractual milestone meet certain expense share alliance partner base contractual agreement expense manage global research development organization approximately billion total spend attribute development activity remainder attribute preclinical research activity expense vary period number reason include time upfront milestone licensing payment research development expense increase primarily million expense relate amylin acquisition include million relate accelerate vest amylin stock option restrict stock unit partially offset favorable foreign exchange net impact upfront milestone licensing payment iprd impairment charge refer specify item include nongaap financial measure amount attribute period iprd impairment charge relate project previously acquire medarex inc medarex acquisition inhibitex acquisition include million relate nucleoside inhibitor reduction shinglesassociate pain result unfavorable clinical trial result decision cease development increase attribute higher upfront milestone licensing payment unfavorable foreign exchange additional development cost result acquisition zymogenetic upfront milestone licensing payment million include million payment associate amendment intellectual property license agreement yervoy prior fda approval payment exclusive license develop commercialize certain program compoundsimpairment charge bms intangible asset billion impairment charge recognize development bm inx compound acquire acquisition inhibitex treat hepatitis virus infection discontinue interest patient safety item financial statement note goodwill intangible asset information incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation chargesrecoverie equity net income affiliate impairment loss sale manufacturing operation outlicense intangible asset impairment gain sale product line business asset income receive alliance partner net pension curtailment settlement incomeexpense interest expense increase termination interest rate swap contract high borrowing investment income include million gain sale auction rate security provision restructure primarily attributable employee termination benefit continuous improvement initiative additional employee termination cost approximately million expect incur result workforce reduction european country majority cost recognize completion discussion local worker council subject local regulation expect employee reduction primarily attribute sale force personnel result restructure sanofi otsuka agreement streamline operation challenge market condition europe litigation chargesrecoverie include million share apotex damage award concern plavix partially offset increase reserve product liability pricing sale promotional matter equity net income affiliate primarily related international partnership sanofi decrease result continued impact generic competition international plavix net sale conversion certain territory optout market impact unfavorable foreign exchange impairment loss sale manufacturing operation primarily attribute disposal manufacturing operation latina italy outlicense intangible asset impairment charge relate asset acquire medarex inc medarex zymogenetics acquisition result unfavorable clinical trial result andor abandonment program similar charge million include research development gain sale product line businesse asset primarily relate sale building mexico sale mature brands income alliance partner include income earn sanofi partnership amortization certain upfront milestone licensing payment relate alliance decrease plavix net sale result low development royalty owe sanofi pension settlement charge recognize primary pension plan result annual lump sum payment exceed interest service cost fourth quarter charge include acceleration portion unrecognize actuarial loss similar charge occur future item financial statementsnote pension postretirement postemployment liability detail change primarily relate high acquisition cost loss debt repurchase sale tax reimbursement gain debt repurchase higher upfront milestone licensing receipt nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item significant andor unusual nature evaluate individual basis similar charge gain item recognize prior period reasonably possible reoccur future period nongaap information intend portray result baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar millions accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin collaboration proceed amortization amylin inventory adjustment cost product sell stock compensation accelerate vest amylin award process standardization implementation cost marketing sell administrative stock compensation accelerate vest amylin award upfront milestone licensing payment iprd impairment research development impairment charge bms intangible asset provision restructuring impairment loss sale manufacturing operation gain sale product line business asset pension curtailment settlement acquisition relate item litigation chargesrecoverie upfront milestone licensing receipt outlicense intangible asset impairment loss debt repurchase incomeexpense decrease pretax income income tax item outof period tax adjustment specify tax benefitcharge income taxis decrease net earning specify tax benefit relate capital loss deduction specify tax benefit relate release tax reserve specify prior period specify tax charge relate tax charge additional taxable income earning foreign subsidiary previously consider indefinitely reinveste offshore reconciliation gaap nongaap follow year end december dollar million share datum net earning attributable bms gaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation gaap net earning attributable bms gaap specify item net earning attributable bms nongaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap income tax million income tax benefit attributable million capital loss deduction result tax insolvency inhibitex impact deduction reduce effective tax rate percentage point addition impact effective tax rate substantially lower result primarily favorable earning mix high low tax jurisdiction change earning mix primarily attribute low plavix sale million impairment charge bms intangible asset less extent internal transfer intellectual property transfer select intellectual property right outside exist new product strategy place key asset close manufacturing distribution operational decision favorable earning mix high low tax jurisdiction expect continue exclude impact impairment charge historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation ireland puerto rico favorable tax rate ireland puerto rico grant schedule expire prior american taxpayer relief act act sign law january provision act include retroactive reinstatement tax credit look exception result tax credit look exception benefit recognize quarter detailed discussion income taxis change effective tax rate refer item financial statementsnote income taxis noncontrolle interest noncontrolle interest primarily relate plavix avaproavalide partnership sanofi territory cover america item financial statementsnote alliance collaboration decrease noncontrolle interest result exclusivity loss avaproavalide march plavix increase noncontrolle interest correspond increase net sale plavix summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning attributable noncontrolle interestnet taxis financial position liquidity capital resource net cashdebt position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing current portion longterm debt longterm debt net cashdebt position work capital current net debt position reduction work capital result primarily net cash connection acquisition amylin inhibitex cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis start issue commercial paper meet nearterm domestic liquidity requirement preparation amylin acquisition quarter average commercial paper outstanding million weightedaverage interest rate maximum monthend commercial paper outstanding million outstanding borrowing december likely continue issue commercial paper meet domestic liquidity requirement need investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard item financial statementsnote financial instrument currently separate billion fiveyear revolve credit facility syndicate lender include new facility enter july facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december connection amylin acquisition bm issue billion senior unsecured note register public offering consist million aggregate principal note million aggregate principal note million aggregate principal note bms complete acquisition amylin aggregate purchase price billion bm assume amylin net debt contractual payment obligation lilly total billion substantially repay acquisition finance use exist cash balance issuance commercial paper longterm debt borrowing describe additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivable direct customer currently believe economic condition material impact liquidity cash flow financial flexibility mechanism limit overall credit exposure additional source liquidity sell trade receivable party principally wholesaler japan certain governmentbacked entity italy portugal spain sale trade receivables italy portugal spain million million million sale receivables japan million million million sale agreement allow recourse event uncollectibility retain interest underlie asset sell continue manage operate cash flow initiative design improve work capital item directly affect change sale volume receivables inventory account payable follow change receivables inventory account payable result primarily rapid reduction plavix sale acquisition amylin timing expenditure ordinary course business trail trail december month december month dollar million net sale net sale net trade receivables inventory account payable total credit rating moodys investor service longterm shortterm credit rating currently prime respectively longterm credit outlook remain stable standard poor longterm shortterm credit rating currently respectively longterm credit outlook remain stable upgrade shortterm credit rating fitch rating fitch longterm shortterm credit rating currently respectively longterm credit outlook remain negative fitch lower longterm credit rating july credit rating consider investment grade longterm rating designate low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating designate strong capacity timely repayment cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee pension contribution tax payment ordinary course business billion increase operate cash flow primarily attributable preliminary proceed billion receive astrazeneca consideration enter amylin collaboration partially offset low operating cash flow attribute plavix avaproavalide sale reduction follow exclusivity loss product investing activity cash fund acquisition amylin billion inhibitex billion amira million include million contingent payment zymogenetic million net sale maturity marketable security billion primarily attribute funding amylin acquisition net purchase marketable security million billion primarily attribute time investment time deposit corporate debt security maturity great day invest activity include litigation recovery million financing activity dividend payment billion billion billion dividend declare common share december declare quarterly dividend common share expect pay dividend year share dividend decision quarterly basis board director proceed receive issuance senior unsecured note repayment debt assume amylin acquisition billion management periodically evaluate potential opportunity repurchase certain debt security terminate certain interest rate swap contract prior maturity cash outflow relate repurchase debt million million million proceed termination interest rate swap contract million million million board director increase authorization repurchase common stock billion june common stock repurchase capacity remain billion december cash repurchase common stock billion billion million proceed stock option exercise million include million cash retain excess tax benefit million include million cash retain excess tax benefit million proceed vary period base fluctuation market value stock relative exercise price stock option factor contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability totalc include estimate future interest payment shortterm longterm debt security include accrue interest payable recognize consolidated balance sheet consist primarily accrue interest shortterm longterm debt accrue periodic cash settlement derivative uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table item financial statementsnote income taxis detail table exclude future contribution pension postretirement postemployment benefit plan require contribution contingent numerous factor include minimum regulatory funding requirement fund status plan uncertainty future obligation exclude table contribution international plan expect million item financial statementsnote pension postretirement postemployment liability detail addition commit billion aggregate potential future research development milestone payment party inlicense development program early stage milestone define milestone achieve phase iii clinical trial comprise billion total commit late stage milestone define milestone achieve post phase iii clinical trial comprise billion total commit payment agreement generally payable achievement certain developmental regulatory milestone specific timing predict addition certain royalty obligation calculate percentage net sale agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation item financial statementsnote alliance collaboration information alliance discussion contractual obligation item financial statementsnote pension postretirement postemployment liability note financial instrument note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly gross sale current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross sale inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard applicable critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate recognize revenue persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience addition net sale discussion analysis significant category grosstonet sale adjustment grosstonet sale adjustment follow category grosstonet sale adjustment involve significant estimate judgment information obtain external source net sale discussion analysis significant category grosstonet sale adjustment chargeback related government program business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag cash discount certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag manage healthcare rebate contract discount rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan contract counterpartie hospital group purchasing organization globally begin rebate medicare program include discount company brandname drug patient fall medicare coverage gap rebate require department defense tricare retail pharmacy refund program estimate unpaid unbilled rebate discount present liability million reversal estimate medicare coverage gap discount occur receipt actual invoice medicaid rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual retroactive january minimum rebate medicaid drug sale increase medicaid rebate extend drug manage medicaid plan begin march estimate unpaid unbilled rebate present liability million reversal estimate manage medicaid discount occur receipt actual invoice sale return product typically eligible return month prior month product expiration accordance policy estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product instance expect precipitous decline demand follow loss exclusivity estimate product return present liability reserve million establish plavix avaproavalide december consider relevant factor estimate future retail wholesale inventory work occur loss exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic category defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product reflect gross net adjustment million revenue relate yervoy defer result limited return experience use information external source information external source estimate grosstonet sale adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citigroup pension discount curve plan plan pension expense determine weightedaverage discount rate present value benefit obligation december pension plan determine discount rate discount rate determine plan pension expense reduce additional expense increase approximately million assumed discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately billion expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liabilitie business combination goodwill intangible asset acquire business combination licensing transaction billion december represent total asset asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill fair value intangible asset include iprd typically determine income method method starts forecast net cash flow risk adjust estimate probability technical regulatory success iprd adjust present value appropriate discount rate reflect risk associate cash flow stream asset value market participant view different specific bms view valuation process complex require significant input judgment internal external source valuation required finalize oneyear period consider fact evidence available acquisition date complex judgmental matter applicable valuation process summarize unit account intangible asset value single global asset multiple asset jurisdiction indication consider development stage expect level incremental cost obtain additional approval risk associate development time benefit expect derive future expect patent live jurisdiction intention promote asset global brand estimate useful life asset life expect contribute meaningful cash flow determine consider pertinent matter associate asset include expect regulatory approval date unapproved exclusivity period legal regulatory contractual provision effect obsolescence demand competition economic factor include barrier entry probability technical regulatory success ptrs rate ptrs rate determine base industry average consider respective program development stage disease indication adjust specific information datum know acquisition date subsequent clinical result internal external datum obtain alter ptrs rate materially impact estimate fair value intangible asset subsequent period leading impairment charge projection future revenue estimate consider factor initial market opportunity pricing sale trajectory peak sale level competitive environment product evolution future cost expense estimate consider historical market trend market participant synergy timing level additional development cost obtain initial additional regulatory approval maintain enhance product generally assume initial positive cash flow commence shortly receipt expect regulatory approval typically occur number year actual cash flow attribute project likely different assume projection subject multiple factor include trial result regulatory matter materially change ultimate commercial success asset significantly alter cost develop respective asset commercially viable product tax rate expect future income tax effect market participant tax rate recent valuation typically use tax rate applicable state taxis consider jurisdiction intellectual property hold location research manufacturing infrastructure consider earning repatriation likely tax consequence discount rate discount rate select consider risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset item financial statementsnote acquisition specific detail value assign asset acquire liability assume acquisition amylin inhibitex amira zymogenetics significant estimate utilize time valuation support fair value lead compound acquisition include estimate phase year discount useful life development ptrs rate project positive dollar million fair value rate utilize year acquisition date utilize cash flow commercialize product bydureon byetta symlin recothrom iprd bms inx phase metreleptin phase iii phase peginterferon lambda phase iib impairment goodwill goodwill billion december goodwill test annually impairment enterprise level assess qualitative factor perform quantitative analysis determine likely fair value exceed carry value example qualitative factor assess current year include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year positive negative influence relevant factor assess individually aggregate result conclude additional quantitative testing require discussion goodwill acquire inprocess research development intangible asset item financial statementsnote accounting policiesgoodwill acquire inprocess research development intangible asset intangible asset include iprd intangible asset billion december include license million develop technology right billion capitalize software million iprd million intangible asset test impairment current fact circumstance warrant review iprd require test annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize charge billion include billion charge result discontinue development bms project previously acquire medarex inc inhibitex acquisition result unfavorable clinical trial result additional development cost extend development period decision cease development recognize charge million million relate medarex project development cease iprd closely monitor assess period impairment addition iprd commercial asset subject impairment example impairment charge million recognize related nonkey product recothrom acquire acquisition zymogenetic continue competitive pricing pressure preliminary estimate fair value develop technology right result acquisition amylin billion include billion allocate recentlylaunche single asset bydureon asset monitor change expectation initial valuation include revenue trend operate synergy contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion net valuation allowance billion december billion net valuation allowance billion december defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure believe likely defer tax asset realize addition defer tax asset relate federal state capital loss million recognize december carry year carry forward year realization carryforward dependent generate sufficient capital gain prior expiration million valuation allowance establish item december taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore company complete internal reorganization certain legal entity contribute million tax charge recognize fourth quarter possible tax authority assert additional material tax liability arise reorganization assertion occur company vigorously challenge assertion believe prevail assurance result prior mead johnson nutrition company mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement example mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset agree indemnify mead johnson certain taxis relate business prior completion ipo create restructure facilitate ipo establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi canadian dollar british pound foreign currency forward contract manage foreign exchange risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset portion exposure designate hedge change fair value derivative recognize earning incur estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december realize appreciation negatively affect earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge recognize foreign currency translation component accumulate oci net investment fall equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information item financial statementsnote financial instrument interest rate risk fixedtofloate interest rate swap contract designate fairvalue hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million exclude effect counterparty credit risk realize fair value reduction affect earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk material certain european governmentbacke entity high risk default identify monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio addition entity specific factor historically exposure limited factoring receivables defer revenue collection cash counterpartie factor arrangement suspend factoring receivables spanish portuguese governmentbacke entity limited factoring receivables certain italian governmentbacked entity credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis credit exposure governmentbacke trade receivables greece portugal italy spain approximately million december approximately governmentbacke entity monitor investment counterpartie objective minimize concentration credit risk investment policy place limit time maturity investment individual counterparty policy require investment primarily highly rate corporate financial government government support institution use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation term agreement post collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statement note financial instrument bristolmyers squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense earning income taxis provision forbenefit income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis derivative qualify cash flow hedge unrealize gain realize gain pension postretirement benefit actuarial loss amortization settlement curtailment available sale security unrealize gain realize gain foreign currency translation foreign currency translation net investment hedge total comprehensive incomeloss net taxis comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing current portion longterm debt account payable accrue expense defer income accrue rebate return foreign income taxis payable dividend payable total current liability pension postretirement postemployment liability defer income foreign income taxis payable deferred income taxis liabilitie longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization net defer income taxis stockbase compensation impairment charge proceed amylin diabete collaboration change operate asset liability receivable inventory account payable deferred income foreign income taxis payable net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software proceed sale business invest activity purchase business net cash acquire net cash investing activity cash flow financing activity shortterm debt borrowingsrepayment proceed issuance longterm debt longterm debt repayment interest rate swap termination issuance common stock common stock repurchase dividend pay net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company refer bristolmyer squibb bms company control majorityowned subsidiary intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date codevelopment cocommercialization license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity arrangement material variable interest entity period present use estimate preparation financial statement require use management estimate assumption significant assumption employ estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation presentation depreciation amortization consolidate statement cash flow include depreciation property plant equipment amortization intangible asset defer income provision restructure equity net income affiliate litigation expense net previously present separately consolidate statement earning currently present component incomeexpense revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment certain sale nonus business recognize date receipt purchaser note alliance collaboration discussion revenue recognition relate alliance provision time revenue recognition expect sale return discount rebate estimate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation provision recognize reduction revenue revenue defer right return long exist sufficient historical experience estimate sale return develop new product extension exist line product historical experience product similar therapeutic category income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment recognize tax benefit uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include treasury security government agency security bank deposit time deposit money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include equity net income affiliate incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment length time extent market value cost financial condition investee inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset estimate useful life depreciable asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique level fair value input include discount value estimate future cash flow longlived asset hold sale report low carrying value estimate net realizable value capitalize software eligible cost obtain internal use software significant system project capitalize amortize estimate useful life software insignificant cost obtain software project expense incur business combination business acquire consolidate obtain control acquiree fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill legal audit business valuation business acquisition cost expense incur goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility judgment estimate impact restructuring plan include future termination benefit exit cost incur action place actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency recognize realize legal fee expense incur derivative financial instrument derivative principally management interest rate foreign currency exposure hold trading purpose derivative recognize fair value change fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive income oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long probable occur gain loss immediately recognize earning nonderivative instrument primarily euro denominate longterm debt designate hedge net investment foreign affiliate effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party certain research development payment alliance partner contingent achievement certain predetermine criterion milestone payment achieve prior regulatory approval product expense research development milestone payment connection regulatory approval capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable research development recognize net reimbursement connection collaboration agreement upfront preapproval milestone licensing receipt obtain development defer amortize estimate life product income company future obligation development upfront milestone licensing receipt recognize immediately income amortization period upfront license milestone receipt assess determined consider term arrangement note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization utilize responsible development delivery product market regional commercial organization distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief operating decision maker chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage global gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation select geographic area information follow net sale property plant equipment dollar millions united statesa europeb rest worldc otherd total include puerto rico include russia turkey include japan china canada australia brazil country include royaltyrelate revenue sale attribute supply agreement net sale key product follow year end december dollar millions plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide eliquis apixaban abilify aripiprazole reyataz atazanavir sulfate sustiva efavirenz franchise baraclude entecavir erbitux cetuximab sprycel dasatinib yervoy ipilimumab orencia abatacept nulojix belatacept onglyzakombiglyze saxagliptinsaxagliptin metformin byetta exenatide bydureonexenatide extendedrelease injectable suspension mature product net sale note alliance collaboration alliance collaboration utilize party development commercialization certain product collaboration include arrangement access intellectual property research development manufacturing andor commercial capability arrangement enter order share risk reward relate specific program product specific divestiture strategy note operating result associate alliance collaboration generally treat follow product revenue bms sale include net sale royalty collaboration profit share distribution fee include cost good sell postapproval milestone payment partner defer amortize useful life relate product cost product sell cost sharing reimbursement offset applicable operating expense payment bms attribute upfront pre approval base milestone licensing payment defer amortize estimate useful life relate product incomeexpense reduction cost product sell amylin diabetes collaboration income expense attribute collaboration noncore activity supply manufacture arrangement compensation optingout commercialization certain country include incomeexpense partnership joint venture consolidated account equity method accounting relate cash receipt distribution treat operate cash flow sanofi bms agreement sanofi codevelopment cocommercialization avaproavalide angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy plavix platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place bms act operating partner own majority control interest territory cover americas australia consolidate country partnership result territory sanofis share result reflect noncontrolle interest bms recognize net sale territory comarkete country outside territory germany italy irbesartan spain greece royalty owe sanofi include cost product sell development royalty sanofi act operating partner own majority control interest territory cover europe asia bms ownership interest territory include equity net income affiliate distribution profit relate partnership include operating activity bms sanofi separate partnership governing copromotion irbesartan sanofi pay bms million acquisition interest irbesartan license formation alliance summarize financial information relate alliance follow year end december dollar million territory cover americas australia net sale royalty expense noncontrolle interest pretax distribution sanofi territory cover europe asia equity net income affiliate distribution bms net sale europe comarkete country amortization incomeexpense irbesartan license fee supply activity development optout royalty incomeexpense december dollar million investment affiliate territory cover europe asia defer income irbesartan license fee noncontrolle interest follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale cost product sell gross profit marketing sell administrative advertising product promotion research development incomeexpense net income current asset current liability cost product sell include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory remain current asset current liability consist thirdparty trade receivables inventory amount bms sanofi purchase inventory royaltie expense reimbursement september bms sanofi restructure term codevelopment cocommercialization agreement discuss effective january subject receipt regulatory approval certain country sanofi assume worldwide operation alliance exception plavix puerto rico alliance plavix market continue unchanged december term original alliance arrangement exchange right assume sanofi bms receive quarterly royalty january december terminal payment sanofi million end ongoing dispute company resolve include onetime payment million bms sanofi relate avalide supply disruption accrue otsuka bms worldwide commercialization agreement otsuka pharmaceutical ltd otsuka codevelop copromote abilify treatment schizophrenia bipolar mania disorder major depressive disorder exclude certain asian country portion amend commercialization manufacturing agreement expire expect loss product exclusivity april contractual share abilify net sale recognize bms germany france spain bms receive thirdparty net sale country thirdparty customer invoice bms behalf otsuka alliance revenue recognize abilify ship risk reward ownership transfer party customer bms recognize net sale certain country exclusive distributor product exclusive right sell abilify bms purchase product otsuka perform finish manufacture sale thirdparty customer bms otsuka term amend agreement bm pay otsuka million amortize reduction net sale expect loss exclusivity april unamortized include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify bms receive additional reimbursement otsuka cost incur bms excess resource requirement specify agreement begin january bm receive follow percentage annual net sale net sale initially recognize adjusted reflect actual level net sale share net sale billion billion billion billion billion billion billion billion billion excess billion commercialization agreement amend october require otsuka assume responsibility provide funding sale force effort effective january consideration bm pay otsuka million january responsible funding certain operating expense million million million otsuka reimburse bms sale force effort provide march begin april otsuka assume responsibility provide funding sale force effort bms otsuka enter oncology collaboration sprycel ixempra ixabepilone japan european union market oncology territory collaboration fee classify cost product sell pay otsuka base follow percentage annual net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product commercial operational expense relate product territory excess million begin otsuka copromote sprycel japan exercise right copromote market begin january extension oncology collaboration include changeofcontrol provision case acquisition bms acquire company compete product abilify new company assume abilify agreement amend oncology collaboration exist today acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right bms abilify agreement amend agreement provide event generic competitor abilify january bms option terminate abilify april amendment agreement previously amend remain force bms exercise option bms receive payment otsuka accord predetermine schedule oncology collaboration terminate time oncology collaboration continue truncated period accord predetermine schedule agreement remain unchanged expire june country bms exclusive right sell abilify agreement expire later april expiration applicable patent datum exclusivity country addition million extension payment total milestone pay otsuka million million expensed iprd remain million capitalize intangible asset amortize cost product sell remain life original agreement summarize financial information relate alliance follow year end december dollar million abilify net sale include amortization extension payment oncology product collaboration fee expense royalty expense reimbursement operating expense tofrom otsuka amortization incomeexpense extension payment amortization incomeexpense upfront milestone licensing payment december dollar million asset extension payment intangible asset upfront milestone licensing payment lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lilly acquisition imclone system incorporate imclone codevelopment promotion erbitux necitumumab imcf expire erbitux september bms codevelopment copromotion right product canada japan erbitux indicate use treatment patient metastatic colorectal cancer use treatment squamous cell carcinoma head neck egfr agreement respect erbitux sale north america lilly receive distribution fee base flat rate net sale north america plus reimbursement certain royalty pay lilly bms imclone amend codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan right agreement expire lilly ability terminate agreement determine commercially unreasonable lilly continue erbitux receive marketing approval japan use erbitux treat patient advance recurrent colorectal cancer bms receive pretax profit merck sale erbitux japan share equally lilly bms amortize million license acquisition cost cost product sell bms lilly restructure egfr commercialization agreement describe bms imclone relate necitumumab novel target cancer therapy currently phase iii development nonsmall cell lung cancer company share cost develop potentially commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market november provide notice termination global codevelopment cocommercialization arrangement necitumumab imcf fully human monoclonal antibody investigate anticancer treatment discover imclone alliance company lilly right return lilly termination effective lilly terminate early summarize financial information relate alliance follow year end december dollar million net sale distribution fee royalty expense research development expense reimbursement lilly necitumumab amortization incomeexpense upfront milestone licensing payment commercialization expense reimbursement tofrom lilly japan commercialization profit sharing incomeexpense net december dollar million intangible asset upfront milestone licensing payment bms acquire amylin pharmaceuticals inc amylin august note acquisition information amylin previously enter settlement termination agreement lilly collaboration global development commercialization byetta bydureon exenatide product party agree transition responsibility product amylin transition operation complete lilly transition nonus operation amylin september bms provide notification lilly bms assume essentially nonus operation exenatide product half terminate lillys exclusive right nonus commercialization exenatide product subject certain regulatory condition bms responsible nonus loss incur lilly maximum million entitle tiere royalty transition complete promissory note assume acquisition amylin aggregate billion repay lilly gilead bms gilead sciences inc gilead joint venture develop commercialize atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen treatment human immunodeficiency virus hiv infection combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead canada europe bms account participation joint venture equity method account net sale bulk efavirenz component atripla defer combined product sell thirdparty customer net sale efavirenz component base relative ratio average respective net selling price truvada sustiva summarize financial information relate alliance follow year end december dollar million net sale equity net loss affiliate astrazeneca bms astrazeneca pharmaceutical whollyowne subsidiary astrazeneca enter collaboration worldwide development commercialization amylin portfolio product bydureon byetta symlin metreleptin currently development arrangement base framework exist diabetes alliance agreement discuss include equal sharing profit loss arise collaboration astrazeneca indicate intent establish equal governance right certain key strategic financial decision collaboration pende require antitrust approval certain international market bms receive preliminary proceed billion astrazeneca consideration enter collaboration include million include accrue expense expect reimburse astrazeneca remain billion account defer income amortize reduction cost product sell prorata basis estimate useful life relate longlived asset assign purchase price allocation primarily intangible asset weightedaverage estimate useful life year property plant equipment weightedaverage estimate useful life year net proceed bms receive astrazeneca consideration enter collaboration subject certain adjustment include right receive additional million astrazeneca exercise option equal governance right bms astrazeneca agree share certain tax attribute relate amylin collaboration preliminary proceed billion bm receive astrazeneca include million relate sharing certain tax attribute addition bms continue maintain worldwide diabete codevelopment cocommercialization agreement astrazeneca onglyza kombiglyze saxagliptin metformin hydrochloride extendedrelease komboglyze saxagliptin metformin immediaterelease market forxiga dapagliflozin agreement saxagliptin exclude japan document specifically note refer kombiglyze komboglyze kombiglyze forxiga approve november onglyza forxiga discover bms kombiglyze codevelope astrazeneca company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis share development cost exception forxiga development cost japan bear astrazeneca bms manufacture product bms opt decline involvement cocommercialization product certain country bms global commercialization network instead receive compensation base net sale record astrazeneca country bm receive million upfront milestone licensing payment relate saxagliptin date receive additional million salesbased milestone bms receive million upfront milestone licensing payment relate dapagliflozin date include million receive january potentially receive additional million development regulatory milestone additional million salesbased milestone bms entitle reimbursement capital expenditure relate amylin summarize financial information relate alliance follow year end december dollar million net sale profit share expense commercialization expense reimbursement tofrom astrazeneca research development expense reimbursement tofrom astrazeneca amortization incomeexpense upfront milestone licensing payment recognize cost product sell incomeexpense upfront milestone licensing payment receive amylinrelate product saxagliptin dapagliflozin december dollar millions deferred income upfront milestone licensing payment amylinrelate product saxagliptin dapagliflozin pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms prevention treatment atrial fibrillation arterial thrombotic condition eliquis approve japan december pfizer fund development cost initial development plan effective january company jointly develop clinical marketing strategy share commercialization expense profit equally global basis certain country bm global commercialization network pfizer commercialize eliquis pay compensation bms base percentage net sale bms manufacture product bms receive million upfront milestone licensing payment eliquis date include million receive february receive additional million development regulatory milestone payment defer amortized estimate useful life product income summarize financial information relate alliance follow year end december dollar million net sale commercialization expense reimbursement tofrom pfizer research development reimbursement tofrom pfizer amortization incomeexpense upfront milestone licensing payment upfront milestone licensing payment receive december dollar millions deferred income upfront milestone licensing payment valeant bms pharmaswiss whollyowne subsidiary valeant pharmaceuticals international inc valeant enter collaboration certain mature brand product europe connection collaboration valeant responsible marketing promotion distribution sale product relate regulatory matter cover territory bms responsible maintenance product intellectual property supply product collaboration expire december time valeant right purchase trademark intellectual property price determine base multiple sale right exercise right transfer valeant collaboration period revert bms consideration enter collaboration bms receive million start collaboration period allocate license right transfer valeant million option purchase remain asset end collaboration million allocation base estimate fair value option element consider market factor include analysis estimate excess fair value mature brand business potential purchase price option purchase trademark intellectual property exercise december fair value option record liability change estimate fair value option liability recognize result operation remain million recognize alliance revenue term collaboration bms recognize revenue collaboration period supply product provide certain information technology regulatory order process distribution transitional service exchange fee month collaboration note acquisition amylin pharmaceuticals inc acquisition august bms complete acquisition outstanding share amylin biopharmaceutical company focus discovery development commercialization innovative medicine treat diabete metabolic disease acquisition cost million include expense bms obtain commercialization right amylin primary commercialize asset bydureon onceweekly diabete treatment byetta daily diabete treatment glucagonlike peptide glp receptor agonist approve certain country improve glycemic control adult type diabete bms obtain commercialization right symlin pramlintide acetate amylinomimetic approve adjunctive therapy mealtime insulin treat diabete goodwill generate acquisition primarily attribute expansion diabetes franchise iprd attribute metreleptin analog human hormone leptine study develop treatment diabetes andor hypertriglyceridemia pediatric adult patient inherit acquire lipodystrophy estimate useful life cash flow utilize value metreleptin assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result inhibitex inc acquisition february bms complete acquisition outstanding share inhibitex inc inhibitex clinicalstage biopharmaceutical company focus develop product prevent treat infectious disease acquisition cost million include expense bms obtain inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase development treatment chronic hepatitis virus infection goodwill generate acquisition primarily attribute potential offer portfolio therapy choice hepatitis virus infection provide additional level sustainability bmss virology pipeline iprd primarily attribute inx inx expect effective combination therapy assume market participant inherently maintain franchise synergy attribute maximize cash flow exist virology pipeline asset cash flow utilize value inx include synergy assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result august company discontinue development inx interest patient safety result company recognize noncash pretax impairment charge billion relate iprd intangible asset quarter information discussion impairment charge note goodwill intangible asset amira pharmaceuticals inc acquisition september bms complete acquisition outstanding share amira pharmaceuticals inc amira million cash plus separate contingent million payment achievement certain development salesbase milestone contingent payment fourth quarter purchase price amira include estimate fair value total contingent consideration million record liability acquisition cost million include expense amira privatelyheld biotechnology company primarily focus discovery development therapeutic product treatment cardiovascular fibrotic inflammatory disease acquisition provide bms right develop commercialize complete phase clinical study remainder amira lysophosphatidic acid receptor antagonist program researcher fibrotic expertise preclinical autotaxin program goodwill generate acquisition primarily attribute acquire scientific expertise fibrotic disease allow expansion new therapeutic class contingent liability estimate utilize model assess probability achieve milestone discount potential payment base expect timing estimate evaluate contingent liability consistent evaluate acquire iprd discount rate payment consistent market debt yield noncallable publiclytraded bond bms similar maturity estimate potential payment date fair value measurement base significant input observable market represent level measurement zymogenetics inc acquisition october bms complete acquisition outstanding share common stock zymogenetics inc zymogenetics october acquisition costs million include expense zymogenetic focus develop commercialize therapeutic proteinbase product treatment human disease company collaborate development peginterferon lambda novel interferon phase iib development acquisition date treatment hepatitis virus infection acquisition provide company right develop commercialize peginterferon lambda bring prove capability therapeutic protein revenue recothrom fda approve specialty surgical biologic goodwill generate acquisition primarily attribute ownership right peginterferon lambda final purchase price allocation zymogenetic amira inhibitex preliminary purchase price allocation pende final valuation intangible asset defer income taxis amylin follow dollar million identifiable net asset amylin inhibitex amira zymogenetics cash marketable security inventory property plant equipment develop technology right iprd asset debt obligation liability defer income taxis total identifiable net asset goodwill purchase price allocate cash pay acquisition amylin include payment million outstanding common stockholder million holder stock option restrict stock unit include million attribute accelerate vest account stock compensation expense quarter result operation acquire company include consolidated financial statement acquisition date revision goodwill preliminary estimate september amylin relate primarily adjustment preliminary allocate fair value acquire iprd decrease million base additional information obtain related future cash flow projection net result defer tax adjustment million pro forma supplemental financial information provide impact acquisition material operating result year acquisition goodwill iprd intangible asset value acquisition nondeductible tax purpose note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructuring note litigation chargesrecoverie equity net income affiliate impairment loss sale manufacturing operation outlicense intangible asset impairment gain sale product line business asset income receive alliance partner net pension curtailment settlement incomeexpense note restructuring follow provision restructuring year end december dollar million employee termination benefit exit cost provision restructure restructuring charge include termination benefit workforce reduction manufacturing sell administrative research development personnel geographic region approximately follow table represent activity employee termination exit cost liability year end december dollar million liability january charge change estimate provision restructure foreign currency translation amylin acquisition spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provisionbenefit effective tax rate reconciliation effective tax rate statutory federal income tax rate earning income taxis dollar million earning income taxis nonus total statutory rate nontax deductible annual pharmaceutical company fee tax effect foreign subsidiary earning previously consider indefinitely reinveste offshore foreign tax effect certain operation ireland puerto rico switzerland state local taxis net valuation allowance federal state foreign contingent tax matter federal research development tax credit tax effect capital loss foreign change effective tax rate tax benefit million attributable capital loss deduction result tax insolvency inhibitex favorable earning mix high low tax jurisdiction primarily attribute low plavix sale million impairment charge bms intangible asset less extent internal transfer intellectual property partially offset contingent tax matter result million charge million benefit unfavorable impact current year rate delay legal enactment research development tax credit extend december change prior period estimate finalize tax return result million benefit change effective tax rate million charge recognize fourth quarter result primarily additional taxable income earning foreign subsidiary previously consider indefinitely reinveste offshore change prior period estimate finalize tax return result million benefit million charge high tax benefit contingent tax matter primarily relate effective settlement remeasurement uncertain tax position million million partially offset unfavorable earning mix high low tax jurisdiction compare prior year nontax deductible annual pharmaceutical company fee effective january tax impact million outofperiod tax adjustment million previously unrecognized net defer tax asset primarily attribute deferred profit relate certain alliance december material prior period american taxpayer relief act act sign law january provision act retroactive reinstatement tax credit look exception result tax credit look exception benefit recognize quarter defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward milestone payment license fee defer income capital loss federal net operating loss carryforward pension postretirement benefit state net operating loss credit carryforward intercompany profit inventory item federal tax credit carryforward foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning total defer tax asset valuation allowance net defer tax asset defer tax liability depreciation repatriation foreign earning acquire intangible asset total defer tax liability defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable current deferred income taxis noncurrent total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization federal tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration capital loss available million carry carry forward foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life management establish valuation allowance defer tax asset likely realize december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal capital loss foreign hold company net operating loss correspond valuation allowance include increase million result statutory impairment charge require consolidated net earning foreign hold company high asset basis statutory purpose basis consolidated financial statement internal reorganization certain legal entity prior period change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million taxis provide approximately billion undistributed earning foreign subsidiary undistribute earning indefinitely invest offshore december additional tax provision require earning repatriate future earning determine remit foreseeable future complexity tax law assumption practicable estimate amount income taxis provide result bms favorable tax rate ireland puerto rico grant schedule expire prior internal reorganization certain legal entity result million charge possible tax authority assert additional material tax liability arise reorganization bms vigorously challenge assertion occur believe prevail assurance result business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation abovea reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expensebenefit penalty expensebenefit uncertain tax benefit reduce deferred tax asset extent uncertainty directly relate asset recognize current non current foreign income taxis payable accrue interest penalty payable unrecognized tax benefit include current noncurrent foreign income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority include limited major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit bms anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms earning attributable unvested restricted share net earning attributable bms common shareholder earning share basic weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share dilute antidilutive weightedaverage equivalent share stock incentive plan note financial instrument financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative carry receivables account payable approximate fair value short term maturity change currency exchange rate interest rate create exposure market risk certain derivative financial instrument available cost effective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize nonbinde quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include treasury security level input utilize observable price similar instrument nonbinde quote price identical similar instrument market active observable input corroborate market datum substantially term asset liability instrument include corporate debt security commercial paper federal deposit insurance corporation fdic insured debt security certificate deposit money market fund foreign currency forward contract interest rate swap contract equity fund fix income fund longterm debt additionally certain corporate debt security utilize thirdparty matrix pricing model use significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment significant unfunded commitment restriction redemption relate equity fix income fund december level derivative instrument value london interbank offer rate libor euro interbank offer rate euribor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably period toperiod volatility underlie foreign currency underlie interest rate drive market condition duration contract credit adjustment volatility significant impact valuation interest rate swap change counterparty credit rating credit default swap spread level unobservable input little market datum available valuation model auction rate security ar float rate security frs portfolio base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity fair value ar determine internally develop valuation base indicative bid receive underlying asset security evidence fair value ars private placement security rate bbb standard poor december represent interest insurance securitization current lack active market frs general lack transparency underlie asset qualitative analysis rely value frs include discussion broker fund manager default risk underlie security overall capital market liquidity availableforsale security cash equivalent follow table summarize availableforsale security december unrealize unrealized gain loss gainloss amortize accumulate accumulate fair fair value dollar million cost oci oci income value level level level december marketable security certificate deposit corporate debt security treasury security equity fund fix income fund ar frs total marketable security december marketable security certificate deposit corporate debt security commercial paper treasury security fdic insure debt security ar frs total marketable security follow table summarize classification availableforsale security consolidate balance sheet december dollar million current marketable security noncurrent marketable security total marketable security money market fund security aggregate million million december respectively include cash cash equivalent value level input cash cash equivalent maintain foreign currency million december subject currency rate risk december million noncurrent available sale corporate debt security frs mature year auction rate security mature year change fair value investment equity fix income fund recognize incomeexpense design offset change fair value certain employee retirement benefit follow table summarize activity financial asset utilize level fair value measurement dollar million fair value january sale unrealize gain fair value december qualifying hedge nonqualifye derivative follow summarize fair value outstanding derivative december december fair value fair value dollar million balance sheet location notional level notional level derivative designate hedge instrument interest rate swap contract asset foreign currency forward contract asset foreign currency forward contract accrue expense cash flow hedge foreign currency forward contract primarily utilize hedge forecast intercompany inventory purchase transaction certain foreign currency forward contract designate cash flow hedge effective portion change fair value temporarily report accumulate oci recognize earning hedge item affect earning notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december net gain foreign currency forward contract qualify cash flow hedge accounting expect reclassify cost product sell year include million pretax gain reclassify month cash flow hedge accounting discontinue forecast transaction long probable occur originally forecast date day hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis ineffective portion change fair value include current period earning earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present net investment hedge nonus dollar borrowing million million designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain loss remeasurement debt recognize foreign currency translation component accumulate oci relate offset long term debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt swap underlie debt benchmark risk hedge record fair value effective interest rate pay fixedtofloate interest rate swap onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize earning reduction interest expense remain life debt fixedtofloate interest rate swap contract billion notional billion notional terminate generate total proceed million include accrue interest million fixedtofloate interest rate swap contract million notional million notional terminate generate total proceed million include accrue interest million nonqualifye foreign exchange contract foreign currency forward contract offset exposure foreign currencydenominate monetary asset liability earning primary objective contract protect dollar value foreign currencydenominate monetary asset liability earning effect volatility foreign exchange rate occur prior receipt settlement dollar contract designate hedge adjust fair value incomeexpense occur substantially offset change fair value underlie foreign currency denominate monetary asset liability earning effect nonqualifye hedge earning significant period present debt obligation shortterm borrowing current portion longterm debt include december dollar millions bank draft shortterm borrowing current portion longterm debt total longterm debt current portion long term debt include december dollar million principal value note note euro note euro note note note note note note debenture debenture debenture mature subtotal adjustment principal value fair value interest rate swap unamortize basis adjustment swap termination unamortized bond discount total current portion longterm debt longterm debt include current portion longterm debt million float rate convertible senior debenture redeem holder par september fundamental change ownership occur debenture callable par time company debenture current conversion price equal conversion rate share principal subject certain antidilutive adjustment quarter billion senior unsecured note issue million aggregate principal note million aggregate principal note million aggregate principal note register public offer interest note pay semiannually note rank equally right payment bmss exist future senior unsecured indebtedness bms redeem note time predetermine redemption price net proceed note issuance million net discount million defer loan issuance cost million average commercial paper outstanding million weightedaverage interest rate maximum month end commercial paper outstanding million outstanding borrowing december substantially billion debt obligation assume acquisition amylin repay quarter include promissory note lilly respect revenue sharing obligation amylin senior note principal value longterm debt obligation million december million million million million remain million fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument debt repurchase activity follow dollar million principal carry value repurchase price notional interest rate swap terminate swap termination proceed total gainloss interest payment million million million net amount related interest rate swap contract bms currently separate billion fiveyear revolve credit facility syndicate lender include new facility receive july financial covenant facility borrowing outstanding revolve credit facility december december million financial guarantee provide form standby letter credit performance bond standby letter credit issue financial institution support guarantee bms affiliate obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivables receivables include december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables receivables net deferred income relate alliance partner recognition income result alliance partner receivables defer income reduce million million december respectively additional information alliance partner note alliance collaboration nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization balance end year note inventory inventory include december dollar million finish good work process raw packaging material inventory inventory expect remain onhand year million december million december include noncurrent asset note property plant equipment property plant equipment include december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million note goodwill intangible asset change carry goodwill follow december dollar million carry goodwill january acquisition amira inhibitex amylin carrying goodwill december include outofperiod adjustment correct purchase price allocation september medarex acquisition million contingent milestone payment prior acquisition medarex purchase price adjustment decrease intangible asset million increase defer tax asset million goodwill million effect adjustment material current prior period intangible asset include december december gross net gross net estimate carry accumulate carrying carry accumulate carry dollar million useful life amortization amortization license year develop technology right year capitalize software year total finitelive intangible asset iprd total intangible asset change intangible asset follow dollar million intangible asset carry january capitalize software addition acquisition amortization expense impairment charge intangible asset net carrying december annual amortization expense intangible asset expect approximately million million million million million million bm announce discontinued development bm know inx nucleotide polymerase nsb inhibitor phase development treatment hepatitis virus infection august decision interest patient safety base rapid thorough ongoing assessment patient phase study voluntarily suspend august bm acquire bms acquisition inhibitex february result termination development program million pretax impairment charge recognize iprd intangible asset impairment charge million recognize related partial writedown fair value develop technology cost relate nonkey product recothrom acquire acquisition zymogenetic develop technology impairment charge result continued competitive pricing pressure note accrue expense accrue expense include december dollar million employee compensation benefit royaltie accrue research development restructure current pension postretirement benefit accrue litigation total accrue expense note sale rebate return accrual reduction trade receivable accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment accrue rebate return note deferred income defer income include december dollar millions upfront milestone licensing receipt atripla defer revenue gain saleleaseback transaction total defer income current portion noncurrent portion upfront milestone licensing receipt amortize expect life product note alliance collaboration information pertain revenue recognition transaction include billion proceed receive astrazeneca relate amylin collaboration defer gain saleleaseback transaction amortize remain lease term relate facility defer income amortization million million million note equity capital common stock excess treasury stock par value retain noncontrolle dollar share million share par value stock earning share cost interest balance january net earning cash dividend declare stock repurchase program employee stock compensation plan distribution balance december net earning cash dividend declare stock repurchase program employee stock compensation plan comprehensive income attributable noncontrolle interest distribution balance december net earning cash dividend declare stock repurchase program employee stock compensation plan comprehensive income attributable noncontrolle interest distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method board director authorize repurchase billion common stock june increase authorization repurchase common stock additional billion repurchase open market private transaction include repurchase plan establish accordance rule securities exchange act stock repurchase program expiration date suspend discontinue time noncontrolle interest primarily relate plavix avaproavalide partnership sanofi territory cover america net earning attributable noncontrolle interest present net taxis million million million corresponding increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis activity include pretax income distribution relate partnership component comprehensive incomeloss oci follow dollar million pretax tax tax year end december derivative qualify cash flow hedgesa unrealize gain realize gain derivative qualify cash flow hedge pension postretirement benefitsb actuarial loss amortization settlement curtailment pension postretirement benefit available sale security unrealize gain foreign currency translation year end december derivative qualify cash flow hedgesa unrealize gain realize gain derivative qualify cash flow hedge pension postretirement benefitsb actuarial loss amortization settlement curtailment pension postretirement benefit available sale security unrealize gain foreign currency translation year end december derivative qualify cash flow hedgesa unrealize gain realize gain derivative qualify cash flow hedge pension postretirement benefitsb actuarial loss amortization settlement curtailment pension postretirement benefit available sale security unrealize gain realize gain available sale securitiesc foreign currency translation realize gainslosse derivative qualify effective hedge recognize cost product sell item financial statementsnote pension postretirement postemployment liability detail realize gainslosses available sale security recognize incomeexpense accumulate balance relate component comprehensive incomeloss oci net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit available sale security foreign currency translation accumulate comprehensive incomeloss note pension postretirement postemployment liability company certain subsidiary sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation fund policy contribute minimum require employee retirement income security act erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit cost define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service costbenefit amortization net actuarial loss curtailment settlement special termination benefit total net periodic benefit cost million pension settlement charge recognize primary pension plan result annual lump sum payment exceed interest service cost fourth quarter charge include acceleration portion unrecognize actuarial loss net actuarial loss prior service cost million expect amortize accumulate oci net periodic benefit cost pension postretirement benefit plan change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement plan amendment actuarial lossesgain retiree drug subsidy benefit pay exchange rate lossesgain benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy benefit pay exchange rate gainslosse fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability fund status recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year pension postretirement liability increase million december corresponding charge comprehensive income result actuarial loss attribute benefit obligation million partially offset high expect return plan asset million actuarial loss result prevail equity fix income market condition reduction interest rate expect return plan asset determine expect rate return calculate value asset refer marketrelated value approximate fair value plan asset december difference assume actual return amortize marketrelated value straightline basis threeyear period gain loss result change actuarial assumption change discount rate difference assume actual experience difference actual expect return plan asset gain loss difference amortize market relate value amortize extent exceed high marketrelated value project benefit obligation respective plan result approximately million related pension benefit expect amortized majority remain actuarial loss amortize life expectancy plan participant plan year expect remain service period plan cost product sell research development marketing sell administrative expense appropriate assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate follow effect percentage percentage dollar million point increase point decrease effect total service interest cost effect postretirement benefit obligation plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity security equity fund fix income fund corporate debt security venture capital limit partnership government mortgage back security treasury agency security shortterm investment fund insurance contract event drive hedge fund collateralize mortgage obligation bond state municipal bond asset back security real estate cash cash equivalent total plan asset fair value investment valuation policy investment class follow level input utilize quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange treasury agency security cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input include observable price similar instrument quote price identical similar instrument market active observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund event drive hedge fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end significant unfunded commitment restriction redemption relate investment value nav december corporate debt security government mortgage back security collateralize mortgage obligation bond asset back security treasury agency security state municipal bond real estate interest classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available equity fund venture capital limited partnership investment classify level fair value hierarchy value estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value insurance contract interest carry contract value approximate estimate fair value base fair value underlie investment insurance company insurance contract hold certain foreign pension plan valuation model corporate debt security collateralize mortgage obligation bond asset back security classify level fair value hierarchy base estimate bid broker thirdparty vendor source utilize expect cash flow stream collateral value include assessment counterparty credit quality default risk discount rate overall capital market liquidity follow summarize activity financial asset utilize level fair value measurement venture capital limited insurance dollar million partnership contract total fair value january purchase sale settlement realize lossesgain unrealized gainslosse fair value december purchase sale settlement realize lossesgain unrealized gainslosse fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international private equity fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage venture capital limited partnership typically value month lag bms company common stock represent plan asset december contribution contribution pension plan million million million contribution international pension plan million million million aggregate contribution international plan expect million estimate future benefit payment pension dollar million benefit benefit year saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense relate plan million million million post employment benefit plan postemployment liability longterm disability benefit million million december respectively expense relate benefit million million termination indemnity plan statutory termination obligation recognize undiscounted basis assume employee termination measurement date liability recognize obligation million million december respectively note employee stock benefit plan shareholder approve stock award incentive plan plan replace stock incentive plan share common stock reserve issuance pursuant stock plan option conversion prefer stock million december share available grant active plan adjust combination plan million december share stock option exercise share unit vest issue treasury stock share actually deliver participant connection award restriction lapse reduce number share reserve share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price common stock grant key employee subject restriction continuous employment restriction expire year period date grant compensation expense recognize vest period stock unit right receive stock end specify vest period voting right market share unit grant certain executive begin vest condition continuous employment vest date payout factor equal payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year longterm performance award year cycle deliver form target number performance share unit number share ultimately issue calculate base actual performance compare earning target performance criterion establish begin performance period award annual goal maximum payout threshold target meet performance period payment plan annual period vest occur end year period stockbase compensation expense base award ultimately expect vest recognize vest period acceleration unvested stock option restrict stock unit connection acquisition amylin result stockbase compensation expense forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate stockbase compensation expense follow year end december dollar million stock option restrict stock market share unit longterm performance award amylin stock option restrict stock unit note total stockbase compensation expense income tax benefit sharebase compensation activity follow longterm stock option restrict stock unit market share unit performance award weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancelle balance december vest expect vest total compensation cost relate sharebased payment award recognize weightedaverage period award expect recognize december follow longterm stock restrict market performance dollar million option stock unit share unit awards unrecognize compensation cost expect weightedaverage period year compensation cost recognize additional information relate sharebased compensation award summarize follow amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit longterm performance award fair value option award vest year stock option restrict stock unit market share unit longterm performance award total intrinsic value stock option exercise year follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding option exercisable weighted weight average weighted average weight remain average remain average number contractual exercise aggregate contractual exercise aggregate outstanding life price intrinsic number life price intrinsic range exercise price thousand year share value exercisable year share value aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december fair value assumption fair value restrict stock unit longterm performance award determine base closing trading price company common stock grant date begin fair value performance share unit grant discount participate dividend fair value performance share unit grant prior discount riskfree interest rate date grant participate dividend fair value market share unit estimate date grant model apply multiple input variable determine probability satisfy market condition model use follow input variable expect volatility riskfree interest rate dividend yield expect volatility base year historical volatility level company common stock current imply volatility fouryear riskfree interest rate derive federal reserve base market share unit contractual term expect dividend yield base historical dividend payment note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum rental commitment operate lease expense million million million sublease income material period present note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product sale generic competition intellectual property plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage expect damage material company plavix previously disclose yes pharmaceutical development service gmbh yes pharmaceutical file application marketing authorization germany alternate salt form clopidogrel application rely datum study originally conduct sanofi bms plavix subject datum protection sanofi bms file action yes pharmaceutical partner administrative court cologne object marketing authorization matter currently pende specific marketing authorization withdraw market resolution lawsuit expect material impact company plavix canada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid june sanofi file defense impeachment action file suit apotex infringement patent trial complete june december federal court canada issue decision patent invalid sanofi appeal decision generic company enter market decision expect later year abilify previously disclose otsuka file patent infringement action teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceutical sun zydus pharmaceuticals usa inc zydus apotex relate patent patent cover aripiprazole expire april include additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka abilify nonjury trial district court district new jersey district court tevabarr apotex complete august november district court uphold validity enforceability patent maintain main patent protection abilify april district court rule defendant generic aripiprazole product infringe patent permanently enjoin engage activity infringe patent include market generic product patent include sixmonth pediatric extension expire sandoz synthon sun zydus bind district court decision december tevabarr apotex appeal decision court appeal federal circuit federal circuit federal circuit affirm district court decision june apotex file petition rehear banc deny december united states supreme court deny apotexs petition writ certiorari request appeal federal circuit decision conclude matter atripla april teva file abbreviate new drug application anda manufacture market generic version atripla atripla single tablet threedrug regimen combine company sustiva gilead truvada time company patent right cover sustivas composition matter method use challenge teva send gilead paragraph certification letter challenge orange bookliste patent atripla atripla product joint venture company gilead gilead file patent infringement action teva district court southern district new york sdny january company receive notice teva amend anda challenge additional orange bookliste patent atripla march company merck sharp dohme corp merck file patent infringement action teva sdny relate patent claim crystalline polymorph form efavirenz march gilead file patent infringement action teva sdny relate orange bookliste patent atripla trial expect possible time reasonably assess outcome lawsuit impact company baraclude august teva file anda manufacture market generic version baraclude company receive paragraph certification letter teva challenge orange bookliste patent baraclude patent patent september company file patent infringement lawsuit district court district delaware delaware district court teva infringement february delaware district court rule company invalidated patent company appeal delaware district court decision evaluate legal option final fda approval anda teva launch generic product rapid significant negative impact sale baraclude begin net sale baraclude million june company file patent infringement lawsuit sandoz follow receipt paragraph certification letter challenge orange book list patent party request case dismiss february party file stipulation dismissal case dismiss sprycel september apotex file anda manufacture market generic version sprycel company receive paragraph certification letter apotex challenge orange book list patent sprycel include composition matter patent november company file patent infringement lawsuit district court apotex infringement orange book list patent cover sprycel trigger automatic month stay approval apotexs anda october company receive paragraph notice letter apotex inform company seek approval generic version dosage strength sprycel challenge orange book list patent november bms file patent infringement suit apotex dosage strength district court case consolidate suit file november trial currently schedule september discovery matter ongoing possible time reasonably assess outcome lawsuit impact company sustiva january teva obtain european marketing authorization efavirenz teva tablets february company merck file lawsuit request injunction teva netherlands germany infringement mercks european patent supplementary protection certificate expire november december request injunction grant deny netherlands germany company merck appeal denial request injunction netherland possible time reasonably assess outcome lawsuit impact company general commercial litigation clayworth litigation previously disclose company number pharmaceutical manufacturer name defendant action file california superior court oakland james clayworth bristolmyers squibb company allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant july judgment favor defendant affirm california court appeals july california supreme court reverse california court appeal judgment matter remand california superior court proceeding march defendant motion summary judgment grant judgment enter favor defendant plaintiff appeal decision california court appeal affirm summary judgment defendant october plaintiff file petition seek review california supreme court deny november remain apotex matter relate plavix previously disclose november apotex file lawsuit new jersey superior court entitle apotex inc sanofiaventis seek payment million plus interest calculate rate month date filing lawsuit pay relate breakup march propose settlement agreement relate thethen pende plavix patent litigation apotex april new jersey superior court grant company crossmotion summary judgment motion deny apotexs motion summary judgment apotex appeal decision new jersey appellate division reverse grant summary judgment case remand superior court additional proceeding possible time reasonably assess outcome lawsuit impact company january apotex file lawsuit florida state court broward county allege breach contract relate propose settlement agreement apotex relate pende plavix patent litigation apotex seek damage profit allege receive sell generic clopidogrel bisulfate month agreement approve regulator discovery conclude company move summary judgment deny november case schedule trial begin march possible time reasonably assess outcome lawsuit impact company pricing sale promotional practice litigation investigation abilify federal subpoena january company receive subpoena united states attorney office southern district new york request information relate thing sale marketing abilify possible time assess outcome matter potential impact company abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute possible time reasonably assess outcome investigation potential impact company abilify copay assistance litigation march company partner otsuka name codefendant putative class action lawsuit file union health welfare fund sdny plaintiff challenge legality abilify copay assistance program federal antitrust racketeer influence corrupt organization law seek damage company otsuka file motion dismiss complaint possible time reasonably assess outcome litigation potential impact company awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende state court country settle lawsuit bring mississippi louisiana attorney general begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company move vacate decision commonwealth move judgment notwithstanding verdict commonwealth court deny company appeal decision pennsylvania supreme court qui tam litigation march company serve unseal qui tam complaint file sale representative california superior court county los angeles california department insurance elect intervene lawsuit complaint allege company pay kickbacks california providers pharmacy violation california insurance frauds prevention act cal in code discovery ongoe possible time reasonably assess outcome lawsuit impact company product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim file state federal court state include california illinois new jersey new york defendant terminate previously disclose tolling agreement effective september february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation coordinate federal pretrial proceeding plavix product liability relate case possible time reasonably assess outcome lawsuit potential impact company reglan company number defendant numerous lawsuit behalf approximately plaintiff claim personal injury allegedly sustain reglan brand generic drug metoclopramide product indicate gastroesophageal reflux certain gastrointestinal disorder company generic subsidiary apothecon inc distribute metoclopramide tablet manufacture party possible time reasonably assess outcome lawsuit potential impact company resolution pende lawsuit expect material impact company hormone replacement therapy company number defendant masstort litigation plaintiff allege thing hormone therapy product include hormone therapy product manufacture company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer company agree resolve claim approximately plaintiffs february company remain defendant approximately actively pende lawsuit federal state court company hormone therapy product sell company january august resolution remain lawsuit expect material impact company byetta bydureon amylin whollyowne subsidiary company note acquisition lilly codefendant product liability litigation relate byetta bydureon february approximately separate lawsuit pende behalf approximately plaintiff court vast majority case bring individual allege personal injury sustain byetta primarily pancreatitis case claim alleged wrongful death company agree principle resolve claim plaintiff majority case pende california state court judicial council grant amylin petition coordinate proceed california state court case allege harm allege use byetta amylin lilly currently schedule trial singleplaintiff case second quarter reasonably predict outcome lawsuit claim proceed give amylin product liability insurance coverage exist claim future relate claim involve byetta expect damage material company bms august company announce discontinued development bms investigational compound test clinical trial treat hepatitis virus infection emergence safety issue date lawsuit file company texas state court plaintiff remove federal court alleging participate phase study bms suffer injury result thereof agreement principle resolve file claim vast majority claim surface date matter total slightly few patient administer compound dose duration clinical trial resolution remain lawsuit potential future lawsuit expect material impact company environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate thirdpartie cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party new brunswick facility environmental personal injury lawsuit lawsuit file company new jersey superior court behalf current resident new brunswick new jersey live live adjacent company new brunswick facility complaint allege personal injury damage result allege soil groundwater contamination property stem historical operation new brunswick facility claim medical monitoring portion complaint assert claim allege property damage october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose company intend defend vigorously litigation discovery ongoing october additional case file new jersey superior court remove company united states district court district new jersey possible time reasonably assess outcome lawsuit potential impact company north brunswick township board education previously disclose october company contact counsel represent north brunswick board education boe site waste material squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process party expect conduct fact expert discovery follow formal evidentiary hearing write argument hearing likely schedule midtolate addition september township boe file suit party allege contribute waste material site company currently believe responsible additional amount interim payment total million transmit additional possible loss expect material proceeding italy investigation july public prosecutor florence italy italian prosecutor initiate criminal investigation company subsidiary italy bms italy allegation company relate allege activity employee leave company italian prosecutor request interim measure judicial administrator appoint temporarily run operation bms italy october party reach agreement resolve request interim measure result italian prosecutor withdraw request request accept florence court possible time assess outcome underlie investigation potential impact company sec germany investigation october sec inform company begin formal inquiry activity certain company german pharmaceutical subsidiary employee andor agent sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act fcpa company cooperate sec fcpa investigation march company receive subpoena sec subpoena issue connection investigation fcpa primarily relate sale marketing practice country company cooperate government investigation matter note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss share basic earningsloss share dilute cash dividend declare common share cash cash equivalent marketable security total asset longterm debt equity dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning net earning attributable noncontrolle interest bms earning share basic earning share dilute cash dividend declare common share cash cash equivalent marketable security total asset longterm debt equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset include current portion longterm debt follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin collaboration proceed amortization amylin inventory adjustment stock compensation accelerate vest amylin award process standardization implementation cost upfront milestone licensing payment iprd impairment impairment charge bms intangible asset provision restructure pension curtailment settlement gain sale product line business asset litigation chargesrecoverie acquisitionrelate expense outlicense intangible asset impairment loss debt repurchase total income taxtax benefit item specify tax benefit increasedecrease net earning second fourth dollar million quarter quarter quarter quarter year accelerate depreciation asset impairment shutdown cost pension curtailment settlement process standardization implementation cost provision restructure litigation chargesrecoverie gain sale product line business asset upfront milestone licensing paymentsreceipt iprd impairment total income tax benefit item specify tax benefit decrease net earning specify tax benefit relate capital loss deduction specify tax benefit relate release tax reserve specify prior period note subsequent event collaboration medicine company february bms medicine company enter global license year collaboration recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetic net sale recothrom million connection collaboration medicine company responsible sale distribution marketing certain regulatory matter relate recothrom bms responsible exclusive supply product certain asset transfer medicine company start collaboration period primarily recothrom business license agreement regulatory asset bms retain asset relate recothrom include patent trademark inventory collaboration expire february time medicine company right purchase remain asset business hold bms price determine base multiple sale plus cost remain inventory hold bms time option exercise asset previously transfer medicine company collaboration period revert bms bms receive million start collaboration period allocate license right transfer medicine company write option record option liability fair value allocation base estimate fair value element consider market factor estimate excess fair value business potential purchase price option purchase exercise change estimate fair value option liability recognize result operation remain proceed receive enter collaboration recognize alliance revenue term collaboration bms recognize alliance revenue collaboration period tiere royalty supply product bms provide certain information technology regulatory order process distribution transitional service exchange fee period month commence start collaboration agreement enter collaboration reckitt benckiser group plc february bms reckitt benckiser group plc rbl agree enter license year collaboration overthecounterproduct sell primarily mexico brazil transaction expect close second quarter subject customary closing condition regulatory approval net sale product approximately million connection collaboration rbl responsible sale distribution marketing certain regulatory matter bms responsible exclusive supply product certain limited asset expect transfer rbl start collaboration period primarily market authorization employee directly attribute business bms retain asset relate business include patent trademark inventory collaboration period expiration collaboration rbl right purchase remain asset business hold bms price determine base multiple sale plus cost remain inventory hold bms time option exercise asset previously transfer rbl collaboration period revert bms bms expect receive proceed million start collaboration period allocate license right transfer rbl write option record option liability fair value allocation base estimate fair value element consider market factor change estimate fair value option liability recognize result operation remain proceed receive enter collaboration recognize alliance revenue term collaboration bms recognize alliance revenue collaboration period tiere royalty supply product bms provide certain information technology regulatory order process distribution transitional service exchange fee period month commence start collaboration report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission permit sec guidance exclude amylin management assessment internal control financial reporting december amylin financial statement amount constitute total asset include billion acquire develop technology right inprocess research development total net sale company consolidate financial statement amount pretax loss million year end december base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting august bristolmyers squibb company company complete acquisition amylin pharmaceuticals inc amylin represent material change internal control financial reporting management assessment effectiveness amylin operation utilize separate information accounting system process possible complete evaluation review internal control financial reporting completion acquisition management intend complete assessment effectiveness internal control financial reporting amylin year acquisition date change internal control financial reporting fourth quarter reasonably likely materially affect company internal control financial reporting item information report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission describe management report internal control financial reporting management exclude assessment internal control financial reporting amylin pharmaceuticals inc amylin acquire august financial statement amount constitute total asset include billion acquire develop technology right inprocess research development total net sale company consolidate financial statement amount pretax loss million year end december accordingly audit include internal control financial reporting amylin company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item item